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Abstract 
37.9 million people worldwide are living with HIV. Nearly half of these individuals 
develop HIV-associated neurocognitive disorder (HAND). Symptoms range from 
subclinical cognitive deficits to severe dementia that impairs daily function and may cause 
death. Combination antiretroviral therapy (cART) has significantly decreased the 
incidence of severe HIV dementia and encephalitis; however, HAND prevalence remains 
high and may be increasing due to the prolonged life span of HIV patients. Currently, there 
is no effective treatment for improving cognitive function in HAND patients. Thus, 
understanding the mechanism and possible avenues for modulating HIV-induced 
cognitive decline is important. HIV neurotoxicity is mainly mediated by factors released by 
infected cells. The HIV envelope protein, gp120, is shed by infected cells and is a potent 
neurotoxin causing excitotoxicity and loss of excitatory synapses. Synaptic damage is 
reversible and correlates with cognitive decline in HAND patients. 
In this dissertation, I explored mechanisms of HIV gp120-induced changes in the 
number of excitatory and inhibitory synapses. Balance between excitatory and inhibitory 
synapses is important for controlling network excitability and maintaining normal neural 
function. The endocannabinoid (eCB) system and NMDA receptors (NMDARs) were 
investigated for their role in gp120-induced synaptotoxicity. HIV gp120 induces loss of 
excitatory synapses via a neuroinflammatory pathway; the endocannabinoid (eCB) 
system is a potential target to modulate neuroinflammation. In the first study, I 
demonstrated that inhibition of monoacylglycerol lipase (MGL), the enzyme that degrades 
the eCB 2-arachidonoylglycerol (2-AG), using the specific inhibitor JZL184, blocked 
gp120-induced excitatory synapse loss. Inhibition of MGL suppressed gp120-induced 
release of the inflammatory cytokine interleukin-1β (IL-1β) through enhanced activation of 
cannabinoid type 2 receptors (CB2Rs), and decreased production of prostaglandin E2 
(PGE2) further decreases neuroinflammation. 
In the second study, I showed that gp120 increases the number of inhibitory 
synapses through the same IL-1β-mediated neuroinflammatory pathway. Activation of the 
tyrosine kinase Src potentiated GluN2A NMDARs to overcome a tonic suppression of 
inhibitory synapses by p38 mitogen-activated protein kinase. 
In the third study, a mechanism for excitatory synaptogenesis was examined. I 
showed that presynaptic GluN2B NMDARs control spontaneous glutamate release, and 
iv 
 
inhibition of these receptors induces synaptogenesis when evoked neurotransmission is 
impaired. 
Taken together, these studies elucidate mechanisms of gp120-induced 
synaptotoxicity. Decreased excitatory and increased inhibitory synaptic input may be 
adaptive mechanisms through which neurons counteract excessive excitation-induced by 
HIV neurotoxins. Because these synaptic changes correlate with cognitive decline, they 
may indicate that a neuroprotective mechanism has gone awry. By determining the 
pathways activated by HIV gp120, this dissertation provides new insight into 
synaptotoxicity-associated with HAND and identifies novel targets for therapeutic agents 
that provide neuroprotection. 
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I. HIV pathogenesis, virology and treatment 
Human immunodeficiency virus (HIV) attacks the immune system and, in 
advanced stages, causes acquired immunodeficiency syndrome (AIDS), one of the 
deadliest diseases in human history. Currently, about 37.9 million people are infected with 
HIV including 1.7 million children (<15 years old) (UNAIDS, 2019). 0.8 % of adults among 
15 – 49-year-olds worldwide are living with HIV (WHO Global Health Observatory, 2018). 
About 59 % of the infected patients are receiving effective antiretroviral therapy and the 
prevention of HIV has improved greatly over the years (WHO Global Health Observatory, 
2018). Despite that, the fight against HIV/AIDS continues. 
HIV is mainly transmitted through sexual contact across mucosal surfaces, 
maternal-infant exposure, and percutaneous inoculation (Shaw and Hunter, 2012). 
Ordinary day-to-day contacts such as shaking hands, hugging or sharing personal objects 
will not cause infection. Primary HIV infection causes non-specific symptoms such as 
fever, headache, fatigue, rash, and joint pain (Bollinger et al., 1997; Vanhems et al., 1999; 
Lavreys et al., 2000). As disease progresses, decreased CD4-positive lymphocytes and 
increased plasma viral load are detected (Mellors et al., 1997). Without treatment, HIV 
further advances to AIDS by depleting CD4-positive lymphocytes to below 200 cells/mm3 
(Osmond et al., 1994; Vlahov et al., 1998). Marked immune activation and inflammation 
accompany HIV infection. Natural killer cells and neutralizing antibodies mediate an 
increase in innate host immune response shortly after infection; residual inflammation is 
induced by HIV proteins and co-infections during chronic stages of the disease (Appay 
and Sauce, 2008; Maartens et al., 2014). Although innate immune response is critical for 
viral control, HIV mutations emerge and strictly limit this effect (Alter et al., 2011; Elemans 
et al., 2017). Immunodeficient patients can develop severe opportunistic infections, 
respiratory disorders, cancers, and neurological complications such as peripheral nervous 
system disorders and HIV-associated neurocognitive disorder (HAND) (Crowe et al., 
1991; Laga et al., 1992; Wallace et al., 1993; Price, 1996; Wallace et al., 1997; McArthur 
et al., 2005; Silverberg et al., 2009; Letendre, 2011). 
HIV is an enveloped lentivirus containing a single strand of RNA. The HIV lifecycle 
includes viral entry, reverse transcription, DNA integration, production of viral proteins, 
and viral release (Ferguson et al., 2002; Maartens et al., 2014). Viral entry is the first and 
the most important step of HIV infection. The viral envelope precursor glycoprotein gp160 
is cleaved into gp120 and gp41 that form a trimer of heterodimers gp120/gp41 (Wilen et 
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al., 2012). Gp120 is the membrane surface envelope glycoprotein that identifies and 
interacts with coreceptors, and gp41 is the transmembrane glycoprotein that anchors 
gp120/gp41 complex in the membrane and facilitates the membrane fusion during viral 
entry (Willey et al., 1988; Freed, 2001). Gp120 binds to CD4, a surface receptor expressed 
on macrophages, dendritic cells and CD4-positive T cells, and induces exposure of 
coreceptor-binding sites. C-X-C chemokine receptor type 4 (CXCR4) and C-C chemokine 
receptor type 5 (CCR5) are two chemokine receptors that serve as coreceptors for gp120 
binding. Binding of gp120 to coreceptors further triggers membrane fusion and viral entry 
(Wilen et al., 2012; Chen, 2019). 
Two types of HIV virus have been identified: HIV-1 and HIV-2. HIV-1 is the most 
widespread and toxic, and major type of HIV and thus, the focus of many HIV related 
studies. HIV-2 is a less toxic form of HIV and causes fewer disease outcomes (Marlink et 
al., 1994). HIV tropism is mainly determined by coreceptors. Macrophage-tropic (M-tropic) 
HIV variants use CCR5 as coreceptor and are designated as R5. T cells-tropic (T-tropic) 
HIV variants use CXCR4 as coreceptor and are designated as X4 virus (Shioda et al., 
1991; Berger et al., 1999). 
The application of combination antiretroviral therapy (cART) has successfully 
transformed HIV from a fatal infection to a chronic manageable disease (Maartens et al., 
2014) with dramatically increased survival rate (Johnson et al., 2013). Early initiation of 
cART has also been shown to decrease HIV transmission (Cohen et al., 2011). More than 
40 antiretroviral drugs have been approved by the U.S. Food and Drug Administration and 
inhibit viral infection at various steps in virus lifecycle. The antiretroviral drugs include 
nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase 
inhibitors, protease inhibitors, fusion inhibitors, CCR5 antagonists, integrase inhibitors. 
Typical cART contains two or more drugs from one or more drug classes. 
Despite the successful management of disease symptoms, eradication of HIV from 
infected individuals remains unlikely. Even with patients under highly active cART 
treatment, resting CD4-positive T cells and the central nervous system (CNS) can serve 
as latent reservoirs for HIV that can be reactivated and initialize systemic infection (Finzi 
et al., 1997; Lambotte et al., 2003; Siliciano et al., 2003; Thompson et al., 2011). CNS 
viral escape can possibly be attributed to the relatively low brain penetration of 
antiretroviral drugs (Kerza-Kwiatecki and Amini, 1999; Thomas, 2004), infected long-living 
microglia and macrophages in the brain with low turn-over rates (Crowe et al., 2003), and 
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integration of HIV-1 to terminally differentiated cells such as astrocytes (Churchill et al., 
2006). CNS reservoirs account for the wide prevalence of HAND despite of successful 
control of plasma viral load in patients receiving cART. 
II. HIV-associated neurocognitive disorders 
HIV-associated neurocognitive disorder (HAND) represents a spectrum of 
neurocognitive dysfunction caused by HIV infection. HIV-associated dementia (HAD), mild 
neurocognitive disorder (MND), and asymptomatic neurocognitive impairment (ANI) are 
three major forms of HAND. They are categorized based on the interference of daily 
function using neuropsychological and functional assessment (Antinori et al., 2007; Saylor 
et al., 2016). 
About half of HIV-infected individuals develop HAND (Ellis et al., 2007). Before the 
wide application of cART, HAD was the most common form of HAND and almost inevitably 
led to death (Ellis et al., 1997). Deployment of highly active cART treatment has 
dramatically decreased the incidence of severe HAD form of cognitive dysfunction; 
however, the prevalence HAND remains high and will likely increase due to the increased 
life span of HIV-infected patients (Maschke et al., 2000; Valcour et al., 2004; Tozzi et al., 
2007; Heaton et al., 2010; McArthur et al., 2010; Joska et al., 2011). 
HAND is characterized by marked cognitive dysfunction including diminished 
performance on attention measurements, slow speed of information processing, and 
impaired task-dependent functions (Baldewicz et al., 2004; Heaton et al., 2004); motor 
dysfunction and depressive symptoms are also observed (Reger et al., 2002). These 
symptoms seriously impair life quality, everyday function and even survival (Heaton et al., 
1994; Heaton et al., 2004; Albert and Martin, 2014). Additionally, conversion from ANI to 
more severe forms of cognitive dysfunction is common in the later stages of HAND 
patients under cART (Grant et al., 2014). Thus, early clinical intervention in addition to 
cART is important for controlling HAND progression. 
III. HAND pathogenesis and mechanism of HIV neurotoxicity 
Introduction of cART has fundamentally shifted the pathophysiology of HAND. 
Neuronal loss and encephalitis, historically considered to play central role, are no longer 
the main pathophysiological foundation for HAND (Gelman, 2015) and do not correspond 
closely to cognitive impairment in HAND patients (Adle-Biassette et al., 1999). In contrast, 
non-apoptotic neural dysfunction such as damage to synaptodendritic connections and 
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disturbance in neural network homeostasis are more closely associated with cognitive 
impairment in patients with MND and ANI, the most prevalent forms of HAND (Masliah et 
al., 1997; Everall et al., 1999; Ellis et al., 2009). Neural dysfunction rather than neuronal 
loss is an emerging focus of therapeutic strategies for HAND. 
HIV penetrates the blood-brain barrier (BBB) at early stages of infection (Resnick 
et al., 1988). Multiple mechanisms are proposed for HIV brain entry. The most commonly 
accepted “Trojan Horse” hypothesis dictates that infected circulating monocytes 
transmigrate across the BBB in response to chemotactic signals (Nath, 1999; Gonzalez-
Scarano and Martin-Garcia, 2005), and subsequently infect macrophages (Fischer-Smith 
et al., 2008), microglia (Dickson et al., 1991) and astrocytes (Brack-Werner, 1999). 
Neurons are not infected by HIV (Gonzalez-Scarano and Martin-Garcia, 2005; Kovalevich 
and Langford, 2012); thus, HIV neurotoxicity is mainly through indirect mechanisms 
mediated by neurotoxic factors released by infected cells (Ellis et al., 2007). 
Sustained neuroinflammation is associated with the progression of HAND 
(Anthony et al., 2005; Vera et al., 2016). Infected macrophages and microglia cause 
sustained brain HIV production and stimulate a brain immune response causing release 
of inflammatory cytokines such as interleukin 1-β (IL-1β) and tumor necrosis factor-α 
(TNF-α) (Hong and Banks, 2015); infected astrocytes, although not producing intact virus, 
release toxic viral proteins such as trans-activator of transcription (Tat), negative 
regulatory factor (Nef) and envelope protein gp120 (Brack-Werner, 1999). Viral proteins 
can exert direct neurotoxicity (Krogh et al., 2014), and also activate uninfected 
macrophages and microglia further enhancing cytokine release and neuroinflammation 
(Kaul et al., 2001; Li et al., 2009). 
IV. Current and potential avenues for HAND treatment 
Deployment of cART has significantly decreased the incidence of severe 
conditions of HAND; milder forms are still prevalent. This is in part due to poor penetration 
of most cART drugs through BBB (Strazielle and Ghersi-Egea, 2005; Ellis et al., 2009). 
CART drugs with better CNS-penetrating properties have been shown to reduce CNS viral 
load (Letendre et al., 2008) but their effect on the improvement of neurocognitive function 
remains questionable (Marra et al., 2009; Ellis et al., 2014). In fact, there is increasing 
concern that these drugs themselves are neurotoxic (Etherton et al., 2015) limiting their 
wide application in HAND treatment. Thus, there is great need to develop alternative or 
adjunctive therapeutic strategies for HAND patients. 
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Neuronal injury in HAND is mainly indirect and due to the inflammatory cytokines 
and viral proteins released by infected immune cells and astrocytes. Neuroprotective or 
regenerative agents targeting neuronal repair and preventing further injury have been 
increasingly explored for the treatment of cognitive decline in HAND. Lithium, a drug for 
treatment of bipolar disorder, was shown to prevent spine loss induced by gp120 in vitro 
(Everall et al., 2002). In humans with HAND, administration with lithium associated with 
increased cognitive performance in a single-arm, 12-week study (Letendre et al., 2006). 
However, this drug failed to demonstrate neurocognitive improvement in HAND patients 
in a recent 6-month randomized placebo-controlled trial (Decloedt et al., 2016). 
Memantine, a non-competitive antagonist of NMDA receptors, was shown to prevent tat 
and gp120-induced neurotoxicity in vitro and in transgenic mice (Toggas et al., 1996; Shin 
et al., 2012). However, in a Phase II clinical trial, it did not induce cognitive improvement 
in HAND patients (Schifitto et al., 2007). Intranasal insulin is being investigated as a 
potential therapeutic agent although the mechanism for cognitive improvement is still not 
well understood (Saylor et al., 2016). Minocycline, an antibiotic, was reported to suppress 
CNS inflammation and severity of encephalitis in SIV-infected rhesus macaques (Zink et 
al., 2005). Another agent suppressing neuroinflammation by inhibiting interleukin-1 
receptor (IL-1R) is also being investigated but the therapeutic effect is not clear 
(ClinicalTrials.gov Identifier: NCT02527460). These studies indicate the potential for 
developing neuroprotective agents for HAND patients; however, lack of efficacy in human 
trials has significantly limited the further development of many drugs. Thus, more 
investigations to fully understand the pathophysiological mechanisms of HAND need to 
be conducted and novel therapeutic strategies need to be explored. 
V. HIV-1 gp120: A potent neurotoxin 
HIV envelope protein gp120 is one of the most toxic viral proteins released by 
infected cells and plays critical role in HIV neurotoxicity. The primary function of gp120 in 
the viral life cycle is to identify host cells and facilitate viral entry. Precursor protein gp160, 
encoded by env gene, is cleaved to gp120 and gp41 after translation (Ferguson et al., 
2002). The non-covalently linked gp120/gp41 complex forms a “trimeric spike” on the 
virion surface. C-terminal gp41 contains a cytoplasmic domain, a membrane spanning 
domain and an extracellular domain, and mediates conformational change in viral fusion 
(Arrildt et al., 2012). N-terminal protein gp120 remains completely outside of the viral 
membrane. It consists of 25 β- and 5 α-helical loops and contains five linearly organized 
conserved regions (C1-C5) interspersed with five variable regions (V1-V5) (Cooley and 
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Lewin, 2003). HIV gp120 identifies and interacts with host cell receptors during viral fusion. 
Residues in the conserved regions on either side of V4 interact with host cell receptor 
CD4; both the apex and the base of the V3 loop interacts with coreceptors (Arrildt et al., 
2012). 
HIV gp120 is a potent neurotoxin shed by infected immune cells and astrocytes 
(Kaul et al., 2001) and detected in brain tissues of HAND patients (Jones et al., 2000; 
Nath, 2002). Systemic and intraventricular injection of gp120 causes neurocognitive 
deficits in rats (Spencer and Price, 1992; Epstein and Gendelman, 1993). In a gp120 
transgenic mouse model, brain expression of gp120 closely corresponded with the 
severity of damage in the CNS and this model was shown to mimic the neuronal injuries 
in human (Toggas et al., 1994; Thaney et al., 2018). Treatment with gp120 causes 
disturbed glutamate homeostasis and loss of excitatory synapses in cortical and 
hippocampal cultures (Vesce et al., 1997; Kim et al., 2011). 
HIV gp120 may induce neurotoxicity through multiple pathways. As previous 
mentioned, CXCR4 and CCR5 are coreceptors for gp120-mediated viral entry. These 
chemokine receptors are mainly Gi protein-coupled receptors that not only serve as 
coreceptors for virus but can be activated independently by released gp120 protein itself 
and other endogenous ligands (Busillo and Benovic, 2007; Wu and Yoder, 2009). CXCR4 
and CCR5 are expressed in various types of brain cells including microglia, astrocytes 
and neurons and their activation closely associates with neuroinflammation (Mennicken 
et al., 1999). In fact, gp120 is shown to directly stimulate astrocytes causing glutamate 
mediated neurotoxicity (Vesce et al., 1997), and activate microglia causing release of 
inflammatory cytokines (Kim et al., 2011). It is also reported that nanomolar concentrations 
of gp120 can interact with the glycine binding site of N-methyl-D-aspartate receptors 
(NMDARs) (Fontana et al., 1997). Understanding the primary mechanism for gp120-
mediated neurotoxicity is critical for deciphering mechanisms of HIV neural injury and 
discovering neuroprotective agents. In this work, gp120IIIB from a viral strain that 
specifically binds to CXCR4 is used to investigate the mechanism of neurotoxicity 
associated with gp120. 
VI. Synaptic changes in HAND 
Numerous studies have been conducted to characterize the pathological 
underpinning of HAND. Synaptodendritic damage, rather than neuronal death, 
corresponds well with cognitive decline in HAND (Adle-Biassette et al., 1999; Ellis et al., 
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2007; Saylor et al., 2016). This damage including dendritic beading, aberrant sprouting, 
retraction of dendritic spines, and loss of synaptic connections (Ellis et al., 2009), happens 
at an early stage and milder form of HAND and precedes overt neuronal loss by months 
to years (Bellizzi et al., 2006). 
HIV-related neuroinflammatory factors and viral proteins including gp120 have 
been reported to induce this type of synaptic damage. HIV gp120 induces loss of 
excitatory synapses at concentration as low as 600 pM in vitro (Kim et al., 2011). Loss of 
synaptic density and associated leaning deficits were also observed in transgenic mice 
expressing gp120; this model was shown to mimic neurodegeneration in HIV patients 
(Toggas et al., 1994; Thaney et al., 2018). HIV tat, another widely studied HIV viral protein, 
causes excitatory synapse loss at a low concentration (50 ng/ml) in vitro (Kim et al., 
2008b), and synapse loss-associated cognitive deficits in transgenic mice expressing tat 
and in mice following intraventricular injection of tat (Fitting et al., 2013; Hahn et al., 2015; 
Raybuck et al., 2017). IL-1β, one of the main inflammatory cytokines released by HIV-
infected cells, was also shown to induce loss of excitatory synapses and cognitive 
dysfunction (Mishra et al., 2012; Festa et al., 2015). 
Higher cognitive behaviors require accurate coordination of neurons through a 
complex neural network with stable activity patterns. Such networks are not static; both 
physiological and pathological forces can drive destabilization of the network. For 
example, under physiological conditions, neurons are constantly integrating, transmitting 
and storing information. In long-term potentiation (LTP), the widely accepted cellular basis 
for learning and memory, sustained high-frequency stimulation from presynaptic terminal 
increases synaptic efficacy leading to unconstrained synaptic strengthening (Bliss and 
Collingridge, 1993; Pozo and Goda, 2010; Turrigiano, 2012). To retain excitability and 
maintain the homeostasis of the network, neurons can stimulate multiple mechanisms, 
including synaptic scaling to adjust the strength of all synapses (Turrigiano and Nelson, 
2004; Marder and Goaillard, 2006), regulation of intrinsic excitability (Marder and 
Goaillard, 2006; Turrigiano, 2011), change of the balance between excitatory and 
inhibitory synaptic input (Liu, 2004; Gonzalez-Islas and Wenner, 2006), and compensatory 
adjustment of synapse numbers (Kirov et al., 1999; Turrigiano, 1999; Wierenga et al., 
2006). These mechanisms, collectively termed as “homeostatic plasticity”, form the 
stabilizing force to maintain activity levels in neural network. 
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Gp120, tat and inflammatory cytokines such as IL-1β and TNF-α are all well-
documented excitotoxins causing glutamate and Ca2+ influx-dependent excitotoxicity and 
pathologically disturb the network homeostasis (Dawson et al., 1993; Gelbard et al., 1993; 
Lawrence et al., 1998; Wang et al., 1999). Tat and IL-1β potentiate NMDAR-mediated 
Ca2+ influx (Viviani et al., 2003; Krogh et al., 2014). TNF-α and gp120 inhibit astrocyte 
glutamate reuptake (Fine et al., 1996; Wang et al., 2003); gp120 was also shown to directly 
stimulate astrocytes to increase glutamate release (Vesce et al., 1997). Collectively, these 
data suggest that the early synaptodendritic damage in HAND may be part of a coping 
mechanism for neurons to counteract excessive excitatory input and has gone awry 
leading to functional impairment. This idea is also supported by a previous study that 
showed that tat induced loss of excitatory synapses is through a mechanism that is distinct 
from that leading to neuronal death (Kim et al., 2008b). 
Balance between excitatory and inhibitory synaptic input is also part of the 
homeostatic plasticity mechanism (Liu, 2004; D'Amour J and Froemke, 2015; Hiratani and 
Fukai, 2017). This balance is important for normal network function and disturbing it is 
associated with cognitive dysfunction in many neurological disorders such as Down 
syndrome, autism spectrum disorders and schizophrenia (Gao and Penzes, 2015; Nelson 
and Valakh, 2015; Zorrilla de San Martin et al., 2018). Activity dependent regulation of 
inhibitory synaptogenesis has been reported (Lin et al., 2008; Flores et al., 2015). In HAND 
conditions, tat was shown to increase the number of inhibitory synapses in primary 
hippocampal culture (Hargus and Thayer, 2013). Extra-synaptic γ-aminobutyric acid A 
(GABAA) receptor-mediated tonic inhibition is also increased by gp120 (Green and Thayer, 
2019). Immunostaining of gephyrin, a post-synaptic scaffolding protein of inhibitory 
synapse, was increased in transgenic mice expressing tat; however, in the same study, 
decreased levels of synaptotagmin 2, a marker of GABAergic pre-synaptic terminal, was 
also detected (Fitting et al., 2013). These studies suggest scaling of inhibitory synapse 
number may underly the mechanism for cognitive dysfunction in HAND. 
Damage to excitatory synapses and compensatory increases in inhibitory 
synapses may reveal important targets for therapeutic intervention of HAND. First, these 
changes directly correspond to cognitive deficits in HAND and many other neurological 
disorders. Second, these changes happen at the early stage of disease and often precede 
overt neuronal death (Bellizzi et al., 2006). Neurons still maintain the ability for synaptic 
repair and functional recovery. In fact, studies have indicated that the loss of excitatory 
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and increase of inhibitory synapses are through mechanisms that are distinct from 
neuronal death and both are reversible (Figure 1.1) (Kim et al., 2008b; Shin et al., 2012; 
Hargus and Thayer, 2013; Raybuck et al., 2017). Induction of recovery of excitatory 
synapses was further shown to trigger improvement of cognitive function in mice (Raybuck 
et al., 2017). Thus, further mechanistic understanding of how inhibitory synapses are 
influenced in HAND and strategies to protect and induce recovery of excitatory synapses 
are promising research topics for the treatment of HAND. 
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Figure 1.1 Hypothetical mechanism for HIV gp120 and tat-induced synaptic 
changes. Distinct pathways mediate synaptic changes and neuronal death. Gp120 
induces release of IL-1β that activate IL-1Rs. Tat can directly activate lipoprotein receptor-
related protein (LRP). These processes induce changes in NMDAR function leading to 
subsequent pathways involving activation of Ca2+/calmodulin-dependent protein kinase II 
(CaMKII), Akt kinase, murine double minute 2 (MDM2). MDM2 mediates ubiquitination of 
postsynaptic density protein 95 (PSD95), p53, and microtubule-associated protein 2 
(MAP2), and leads to loss of excitatory synapses. Activation of CaMKII mediates loss of 
excitatory synapses, increase of inhibitory synapses, and activation of cAMP response 
element-binding protein (CREB) which mediates anti-apoptotic pathways. GluN2A-
containing NMDARs regulate changes to excitatory and inhibitory synapses. GluN2B-
containing NMDARs activate neuronal nitric oxide synthase (nNOS) preventing synapse 
recovery, and may mediate pro-apoptotic pathways (Green et al., 2018). Reproduced with 
permission, © 2018, Springer Science Business Media, LLC, part of Springer Nature.  
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VII. Modulation of synapses: endocannabinoid system 
Neuroinflammation and excitotoxicity are two hallmarks of HIV-related 
neurotoxicity. HIV-infected immune cells mediate neuroinflammation; viral proteins 
stimulate uninfected microglia and macrophages enhancing release of inflammatory 
cytokines. Both viral proteins and released inflammatory cytokines cause excessive 
excitotoxic input and induce changes in excitatory and inhibitory synapses. The 
endocannabinoid (eCB) system provides on-demand protection against excitotoxicity and 
neuroinflammation (Marsicano et al., 2003; Walter and Stella, 2004; Wu et al., 2019). 
Two major cannabinoid receptors can be targeted for neuroprotection. 
Cannabinoid type 1 receptors (CB1Rs) are expressed in presynaptic terminals of both 
excitatory glutamatergic and inhibitory GABAergic synapses in hippocampus (Di Marzo et 
al., 2015). Cannabinoid type 2 receptors (CB2Rs) are expressed at low levels in brain 
under healthy conditions, with expression significantly upregulated in microglia and 
macrophages under neuroinflammatory conditions (Howlett et al., 2002; Nunez et al., 
2004; Di Marzo et al., 2015). Both CB1Rs and CB2Rs are Gi/o protein-coupled receptors. 
CB1Rs mediate a retrograde signaling pathway in which depolarized post-synaptic 
neurons rapidly release eCBs to stimulate presynaptic CB1Rs inhibiting further release of 
neurotransmitters (Wilson and Nicoll, 2001). This process causes transient suppression 
of excitation (depolarization-induced suppression of excitation, DSE) or inhibition 
(depolarization-induced suppression of inhibition, DSI) of post-synaptic neurons and is a 
form of short-term synaptic plasticity to control network excitability (Kano et al., 2002; 
Freund et al., 2003; Diana and Marty, 2004). Activation of CB1Rs was shown to alleviate 
excitotoxicity in seizures (Marsicano et al., 2003; Monory et al., 2006; Guggenhuber et al., 
2010). CB2Rs exhibits anti-neuroinflammatory effects (Cabral and Griffin-Thomas, 2009). 
CB2R activation reduces the release of inflammatory cytokines (Klegeris et al., 2003; 
Romero-Sandoval et al., 2009), decreases microglial activation (Malek et al., 2015) and 
inhibits chemotaxis (Romero-Sandoval et al., 2009). In HAND models, direct stimulation 
of CB2Rs suppressed microglial activation and neuroinflammation (Gorantla et al., 2010; 
Hu et al., 2013) leading to protection from loss of excitatory synapses (Kim et al., 2011; 
Purohit et al., 2014). Investigation of direct activation of CB1Rs to protect HIV neurotoxicity 
is rare, probably because of the psychoactive properties of exogeneous cannabinoids 
(Howlett et al., 2002). 
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Modulation of the endogenous CBR ligands anandamide (AEA) and 2-
arachidonoylglycerol (2-AG) provide an alternative and potentially better strategy for 
neuroprotection. AEA is a low-efficacy agonist for CB1Rs and has even lower efficacy for 
CB2Rs. 2-AG is a full agonist for both CB1Rs and CB2Rs (Di Marzo et al., 2015). AEA 
and 2-AG are degraded by fatty acid amide hydrolase (FAAH) and monoacylglycerol 
lipase (MGL) respectively, both generating arachidonic acid (AA) (Blankman and Cravatt, 
2013). AA is the precursor for cyclooxygenase enzymes (COX1 and COX2)-mediated 
production of pro-inflammatory prostaglandins (PGs) in brain (Simmons et al., 2004; 
Rouzer and Marnett, 2009). Thus, inhibiting the degradation of eCBs may enhance the 
activation of CB receptors and decrease production of PGs producing dual protective 
effects on neurons. And because the protective effect is “on-demand” and dependent on 
transient production of eCBs; this strategy will likely exhibit  fewer side effects than direct 
activation of CB receptors. Inhibition of MGL may exert more powerful protective effect 
than inhibiting FAAH because 2-AG is a full against for both CB1Rs and CB2Rs, and the 
AA generated by 2-AG degradation is the main pool for brain production of PGs (Nomura 
et al., 2011; Viader et al., 2015). 
In fact, inhibition of MGL induces potent anti-neuroinflammatory effects (Nomura 
et al., 2011; Grabner et al., 2016). In an Alzheimer’s disease model, MGL inhibition 
induced the recovery of excitatory synaptic spines and this effect was associated with 
cognitive recovery in transgenic mice (Chen et al., 2012). These data suggest a potential 
protective effect of MGL inhibition in HIV-associated synaptodendritic damage with 
potential multiple protective pathways and reduced psychoactive side effects. 
VIII. Modulation of synapses: NMDARs 
The NMDAR is a neuron-specific ionotropic glutamate receptor mediating Ca2+ 
influx into neurons. NMDARs play important roles in regulation of learning and memory 
(Malhotra et al., 1996; Tang et al., 1999; Newcomer and Krystal, 2001) and its dysfunction 
is associated with many neurodegenerative diseases such as Alzheimer’s disease, 
(Snyder et al., 2005), multiple sclerosis (Rossi et al., 2013), and bipolar disorder (Clinton 
and Meador-Woodruff, 2004). HIV neurotoxins cause biphasic changes in NMDAR-
mediated Ca2+ influx (Krogh et al., 2014; Green and Thayer, 2016). These functional 
changes in NMDARs mediate HIV neurotoxin-induced loss of excitatory synapses and 
increase of inhibitory synapses (Kim et al., 2008b; Kim et al., 2011; Hargus and Thayer, 
2013). 
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NMDARs are tetramers composed of two obligatory GluN1 subunits and two 
GluN2 subunits (Cull-Candy et al., 2001). Four types of GluN2 subunits exist: GluN2A, 
GluN2B, GluN2C and GluN2D (Cull-Candy et al., 2001). GluN2A and GluN2B are the most 
abundant forms expressed in hippocampus, an important region controlling learning and 
memory (Monyer et al., 1994; Shipton and Paulsen, 2014). NMDARs are expressed on 
synaptic and extra-synaptic sites of neurons (Papouin et al., 2012). Synaptic NMDARs 
localize to both pre- and post-synaptic terminals (Corlew et al., 2008). 
Previous studies focusing on the non-selective NMDAR antagonist memantine 
(Johnson et al., 2015) showed that the drug induced excitatory synapse recovery in vitro 
(Shin et al., 2012) but, failed to demonstrate effective cognitive improvement in HAND 
patients (Schifitto et al., 2007). Different subtypes of NMDARs with different locations are 
coupled to different pathways and thus, play different roles in regulating neural function. 
Inhibiting GluN2A NMDARs blocked tat-induced loss of excitatory synapses in 
hippocampal neurons but failed to rescue synapses after loss; inhibition of GluN2B 
NMDARs induced recovery of synapses after tat-induced loss but did not block the initial 
loss (Figure 1.1) (Shin et al., 2012; Hargus and Thayer, 2013; Raybuck et al., 2017). Post-
synaptic NMDARs undergo switch from GluN2B to GluN2A during development (Stocca 
and Vicini, 1998); while presynaptic sites retain GluN2B receptors and these receptors 
regulate glutamate release. In particular that regulation of spontaneous release of 
glutamate (Abrahamsson et al., 2017) is important for regulating synaptic strength and 
formation of synapses during development (Crawford et al., 2017; Ramirez et al., 2017). 
Thus, further understanding of the role of different subtypes and locations of 
NMDARs in modulation of HIV-related excitatory and inhibitory synaptic changes will 
provide insight for research on the protection and rescue of synapses. 
IX. Summary of introduction and current studies 
In summary, HAND is a worldwide public health issue influencing nearly half of the 
37.9 million HIV-infected population. CART decreased life-threatening HAD but did not 
change the prevalence of HAND and the drugs may cause neuronal injury themselves. 
Effective symptom-improving agents are not available, creating a great need for thorough 
understanding of mechanisms for cognitive dysfunction and exploration of novel 
therapeutic strategies. Synaptic damage is the most relevant pathological underpinning 
for cognitive deficits in HAND, and HIV neurotoxicity is mainly mediated by released viral 
proteins and inflammatory cytokines. This dissertation focuses on HIV neurotoxin gp120-
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induced changes in excitatory and inhibitory synapses. The eCB system and NMDARs, 
two promising targets for modulating the synaptotoxicity of HIV neurotoxins, were 
examined. 
HIV gp120 is a potent neurotoxin inducing loss of excitatory synapses. Enhancing 
the function of the eCB system induces anti-neuroinflammatory effects in many 
neurological diseases models. In the first study, I used a novel fluorescent recombinant 
antibody-like protein (intrabody) to label excitatory synapses. My study discovered that a 
neuroinflammatory pathway involving activation of microglia and release of inflammatory 
cytokine IL-1β mediates gp120-induced loss of excitatory synapses. Subsequent 
potentiation of NMDARs is also involved in the pathway for synapse loss. A selective 
inhibitor for MGL, JZL184, blocked the loss through both activation of CB2Rs (but not 
CB1Rs) and reduced production of prostaglandin E2 (PGE2). 
My work also discovered that gp120 increases the number of functional inhibitory 
synapses. The same microglia-mediated neuroinflammatory pathway is involved. 
Subsequent Src family kinase-induced potentiation of GluN2A NMDARs mediates the 
upregulation. This pathway overcomes a basal suppression of inhibitory synaptogenesis 
provided by p38 mitogen-activated protein kinase (MAPK). This work is consistent with 
previous work demonstrating that HIV tat treatment increases inhibitory synapse number 
and further supports the idea that a mechanism that controls the homeostasis of neural 
network is stimulated to counteract the excessive excitation that result from exposure to 
HIV proteins (Hargus and Thayer, 2013). 
Finally, to investigate the possible role of NMDARs in synaptogenesis, I used a 
novel spine calcium imaging method. I demonstrated that GluN2B NMDARs on 
presynaptic terminals controls spontaneous release of glutamate. Inhibiting this process, 
when evoked network activity is blocked, induces excitatory synaptogenesis. Previously 
our lab reported that blocking GluN2B-containing NMDARs induces recovery of excitatory 
synapses after the network is impaired (Shin et al., 2012; Raybuck et al., 2017). This work 
supports those findings and may present a mechanism for the regeneration of synapses 
after HIV neurotoxin-induced loss. 
These studies expand our understanding of the neurotoxic mechanisms of HIV 
gp120. Drug discovery focusing on subtypes of NMDARs with specific locations may 
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provide a novel view for the field. Modulation of neuroinflammation through eCB system 
is also a promising therapeutic strategy and may be well tolerated by patients. 
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I. Introduction 
Monoacylglycerol lipase (MGL) hydrolyzes the endocannabinoid, 2-
arachidonoylglycerol (2-AG), to arachidonic acid (AA) and glycerol (Blankman and Cravatt, 
2013). In the brain, hydrolysis of 2-AG by MGL is the principal source of AA for the 
production of prostaglandins (PGs) (Nomura et al., 2011). Thus, inhibition of MGL can 
affect neuronal function by enhancing endocannabinoid signaling (Viader et al., 2015) and 
decreasing PG-mediated inflammation (Nomura et al., 2011; Grabner et al., 2016).  Both 
of these actions might protect the CNS from excitotoxic insult. Activation of the 
endocannabinoid system protects neuronal function in animal models of epilepsy, stroke 
and Alzheimer’s disease (Pacher et al., 2006; Chen et al., 2012). Neuroinflammation 
impairs neuronal function (Heneka et al., 2015), and elevated PG levels contribute to 
neuronal dysfunction in animal models of status epilepticus (Jiang et al., 2013), pain (Zhao 
et al., 2007) and Alzheimer’s disease (Johansson et al., 2015). Here we examined the 
effects of MGL inhibition in an in vitro model of a neuroinflammatory disorder using JZL184, 
a potent and selective inhibitor of MGL (Pan et al., 2009; Grabner et al., 2016). 
HIV-associated neurocognitive disorder (HAND) afflicts almost half of HIV-infected 
individuals (Ellis et al., 2007; Saylor et al., 2016). Cognitive decline in HAND correlates 
closely with synaptodendritic damage such as dendritic pruning and degradation of 
synaptic proteins (Ellis et al., 2007; Ellis et al., 2009). Because HIV does not infect neurons, 
HIV neurotoxicity is indirect and thought to be mediated by a neuroinflammatory response 
to viral proteins and inflammatory cytokines released by infected microglia and 
macrophages (Kaul et al., 2001; Ellis et al., 2007; Saylor et al., 2016). The HIV envelope 
protein, gp120, has been detected in the brain tissue of HAND patients (Jones et al., 2000; 
Nath, 2002), is shed by infected cells (Kaul et al., 2001), and is a potent neurotoxin 
(Toggas et al., 1994). 
Synapse loss is the hallmark of HAND and gp120 induces significant loss of synapses 
in both primary neuronal cultures and transgenic mice (Toggas et al., 1994; Iskander et 
al., 2004; Kim et al., 2011). When applied to hippocampal cultures composed of microglia, 
astrocytes and neurons, gp120IIIB binds to CXCR4 on microglia evoking the release of the 
inflammatory cytokine interleukin-1β (IL-1β) (Viviani et al., 2006; Kim et al., 2011). HIV 
gp120-induced synapse loss is blocked by an IL-1 receptor antagonist (Kim et al., 2011). 
Whether modulating endocannabinoid tone affects this process of neuroinflammatory 
synapse loss is not known. Thus, gp120-induced loss of synapses between hippocampal 
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neurons in culture provides a model to study the potential for inhibition of MGL to protect 
synaptic function. 
The present study demonstrates that JZL184 completely protects from gp120-
induced synapse loss. The contributions of enhanced endocannabinoid tone and reduced 
PGE2-mediated neuroinflammation to synapse protection were determined. The dual 
mechanisms of protection that result from MGL inhibition might be particularly beneficial 
in neurodegenerative disorders with a strong neuroinflammatory component like HAND. 
II. Materials and methods 
Materials 
Drugs used in this study and their pharmacological targets are summarized in 
supplementary Table 1.  Materials were obtained from the following sources: JZL184 from 
the NIDA Drug Supply Program (Research Triangle Institute, Research Triangle Park, 
NC, USA) and Cayman Chemical (Ann Arbor, MI, USA); IL-1β and IL-1ra from R&D 
System (Minneapolis, MN, USA);  AM630, AH6809, JZL 195, LY320135, rimonabant, and 
SR144528 from Tocris Bioscience (Bristol, UK);  arachidonoyl-AMC from Enzo Life 
Sciences (Farmingdale, NY, USA); 4-nitrophenylacetate (4-NPA) from Cayman Chemical 
(catalog number: 705193; Ann Arbor, MI, USA); Dulbecco’s modified Eagle’s medium 
(DMEM), Hanks’ balanced salt solution, fetal bovine serum, horse serum, 
penicillin/streptomycin, fura-2 AM, and glycine from Invitrogen (Carlsbad, CA, USA).  The 
PSD95.FingR-eGFP expression vector (pCAG-PSD95.FingR-eGFP) was generated in 
the laboratory of Don Arnold and obtained from Addgene (catalog number: 46295; 
Cambridge, MA, USA).  The expression vector for tdTomato driven by the synapsin 
promoter was generated by excising tdTomato from pLVX-tdTomato-N1 (Clontech-Takara 
Bio, Mountain View, CA, USA) and inserting it into the pSyn backbone of pSyn-PSD95-
GFP kindly provided by Kirill Martemyanov (Scripps Research Institute, Jupiter, FL, USA).  
HIV-1 gp120IIIB was obtained through the National Institutes of Health (NIH) AIDS Reagent 
Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH 
(catalog number:11784). 
 
Cell culture 
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All animal care and experimental procedures conformed to the Guide for the Care 
and Use of Laboratory Animals published by the U.S. National Institutes of Health. Ethical 
approval was granted by the Institutional Animal Care and Use Committee of the 
University of Minnesota (protocol 1612-34372A). Primary neuronal cultures were prepared 
from fetal tissue collected from 70 timed pregnant Sprague Dawley rats (250-300 g when 
mated) supplied by Charles River Laboratories (Raleigh, North Carolina, USA). Because 
multiple dishes of cells are produced from a single plating, this method reduced the 
number of animals required to complete the study. Prior to tissue collection, the animals 
were housed in the University of Minnesota vivarium for 2–6 d at constant temperature 
and humidity on a 12 h light/dark cycle, with free access to water and standard rat chow. 
Primary rat hippocampal neurons were grown as described previously (Waataja et 
al., 2008) with minor modifications. Dams were killed by CO2 inhalation in an institutionally 
approved and calibrated CO2 chamber. Embryonic day 17 fetuses were rapidly 
decapitated with sharp scissors then hippocampi dissected and placed in Ca2+ and Mg2+ 
free Hanks’ Balanced salt solution. Hippocampi were suspended in DMEM without 
glutamine, supplemented with 10% fetal bovine serum and penicillin/streptomycin (100 U 
mL-1 and 100 µg mL-1, respectively) and dissociated by trituration through flame-narrowed 
Pasteur pipettes of decreasing aperture. Dissociated cells were then plated onto either a 
25 mm round cover glass or a 25 mm round cover glass glued to cover a 19 mm diameter 
opening drilled in the bottom of a 35 mm Petri dish. The cover glass was pre-coated with 
Matrigel (150 µL, 0.2 mg mL-1) (BD Biosciences, Billerica, MA, USA). Cells were grown in 
a humidified atmosphere of 10% CO2 and 90% air (pH 7.4) at 37 °C. On day 1 and day 8 
in vitro, cells were fed by exchanging 75% of the media with DMEM, supplemented with 
10% horse serum and penicillin/ streptomycin. Cells used in this study were grown for 12 
to 16 days in vitro without mitotic inhibitors, resulting in a mixed glial-neuronal culture. 
Using previously described immunocytochemistry methods (Kim et al., 2011), we found 
that these cultures are composed of 24 ± 4% neurons, 55 ± 4% astrocytes and 13 ± 6% 
microglia. 
 
MGL Activity Assay 
MGL activity was measured using a previously described assay (Muccioli et al., 
2008) with minor modifications. Rat hippocampal cultures were untreated or pretreated 
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with various concentrations of JZL184 for 24 h. After pre-treatment, cells were scraped 
and collected in buffer containing 50 mM HEPES (pH 7.4), 1 mM EDTA, 1 µM pepstatin, 
100 µM leupeptin, and 0.1 mg mL-1 aprotinin. The cells were sonicated on ice five times 
for 10 s at 15 s intervals and then centrifuged at 100,000 x g for 50 min at 4 ℃.  After 
resuspending the pellet, the membranes were mixed with the colorimetric substrate for 
lipid hydrolases 4-NPA (catalog number: 705193; Cayman Chemical, Ann Arbor, MI, USA) 
to a final concentration of 202 µM. The mixture was transferred immediately into an Infinite 
M1000 PRO Microplate Reader (Tecan, Männedorf, Switzerland), and absorbance at 405 
nm was monitored every 5 min for 180 min at 37 °C. Protein concentration was measured 
using Pierce Coomassie (Bradford) Protein Assay Kit (catalog number: 23200; 
ThermoFisher Scientific, Minneapolis, MN, USA) according to the manufacturer’s 
instructions.  Enzyme activity was determined from the linear phase of the reaction (15-55 
min) and normalized to protein concentration. 
 
FAAH Activity Assay 
FAAH activity was measured using a previously described assay (Ramarao et al., 
2005) with minor modifications. Rat hippocampal cultures were untreated or pretreated 
with 1 µM JZL195, or 1 µM JZL184 for 24 h. After pre-treatment, cells were scraped and 
collected in buffer containing 50 mM HEPES (pH 7.4), 1 mM EDTA, 1 µM pepstatin, 100 
µM leupeptin, and 0.1 mg mL-1 aprotinin. The cells were then sonicated on ice five times 
for 10 s at 15 s intervals and then mixed with the fluorogenic substrate of FAAH, 
arachidonoyl-AMC (Enzo Life Science, Farmingdale, NY, USA), to a final concentration of 
100 µM. The mixture was transferred immediately into an Infinite M1000 PRO Microplate 
Reader (Tecan, Männedorf, Switzerland), and fluorescence monitored every 5 min for 200 
min at 37 °C (355 nm excitation, 460 nm emission).  Enzyme activity was determined from 
the linear phase of the reaction (0-75 min) and normalized to protein concentration. 
 
Transfection 
Transfection of cultured rat hippocampal neurons was conducted between 11 and 
12 days in vitro using a previously described protocol with minor modifications (Kim et al., 
2011). Briefly, a DNA/calcium phosphate precipitate containing 0.5 µg of total plasmid 
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DNA per well was prepared and allowed to form for 90 min at room temperature. The 
media (conditioned media) was exchanged with DMEM supplemented with 1 mM 
kynurenic acid, 10 mM MgCl2, and 5 mM HEPES to reduce neurotoxicity. The 
DNA/calcium phosphate precipitate was added dropwise to the cells and allowed to 
incubate for 30 min. After the incubation, cells were washed twice with DMEM 
supplemented with 10 mM MgCl2 and 5 mM HEPES to remove leftover precipitate. After 
washing, conditioned media that had been saved at the beginning of the procedure was 
returned to the cells. Experiments were started 48-72 h after transfection.  The calcium 
phosphate method of transfection was chosen because of its low toxicity. 
 
Confocal imaging and image processing 
Transfected cells were imaged with an inverted laser scanning confocal 
microscope (Nikon A1, Melville, NY, USA) using a 60× (1.4 numerical aperture) oil-
immersion objective. Petri dishes containing cells were place in a stage-top incubator (LCI, 
Seoul, Korea) and maintained at 37o C and 10% CO2 during imaging. After imaging, the 
cells were then returned to the cell culture incubator and the coordinates of the computer 
controlled stage were saved to enable repeated imaging of the same neuron for 24-48 h. 
A custom machined jig allowed the Petri dish to be returned to the same location on the 
microscope stage. GFP was excited at 488 nm and emission collected from 500 to 550 
nm. TdTomato was excited at 561 nm and emission collected from 570 nm to 620 nm. 
Optical sections spanning 8 µm in the z-dimension were collected (1 µm per step) and 
combined through the z-axis into a maximum z-projection. GFP puncta were counted in 
an unbiased manner using an algorithm written in MetaMorph 6.2 image processing 
software (Waataja et al., 2008). A threshold set 0.25 times 1 standard deviation above the 
image mean was applied to the tdTomato image. This created a 1 bit image, which was 
used as a mask via a logical AND function with the GFP maximum z-projection. A top-hat 
filter (80 pixels) was applied to the masked GFP image. A threshold set 1.5 standard 
deviations above the mean intensity inside the mask was then applied to the contrast 
enhanced image. Structures between 12 and 80 pixels (0.13-0.86 µm2) were counted as 
postsynaptic densities. The structures were then dilated and superimposed on the 
tdTomato maximum z-projection for visualization. The change in the number of 
PSD95.FingR puncta from 2-3 microscopic fields, each containing one tdTomato filled 
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neuronal soma, from a single dish were averaged and defined as an individual sample 
(n=1). 
 
[Ca2+]i imaging and analysis 
Intracellular Ca2+ concentration ([Ca2+]i) was measured as previously described 
(Krogh et al., 2014). Briefly, cells were incubated in 10 µM fura-2 acetoxymethyl ester 
(fura-2 AM) in 0.04% pluronic acid in HEPES Hanks’ salt solution (HHSS), pH 7.45, for 30 
min at 37 °C. HHSS contained the following (in mM): HEPES 20, NaCl 137, CaCl2 1.3, 
MgSO4 0.4, MgCl2 0.5, KCl 5.0, KH2PO4 0.4, Na2HPO4 0.6, NaHCO3 3.0, and glucose 5.6. 
After loading with indicator, cells were washed in HHSS without fura-2 AM at 37 °C for 10 
min. The cover glass containing loaded and washed cells was transferred to a recording 
chamber, and placed on the stage of an IX71 microscope (Olympus, Melville, NY, USA). 
Cells were imaged using a 20× (0.75 numerical aperture) objective. [Ca2+]i was measured 
by sequential excitation of fura-2 at 340 and 380 nm (8 nm slit width) and emission was 
collected from 490 to 530 nm; image pairs were collected every 1 s. Cells were superfused 
at a rate of 2 mL min-1 with HHSS and responses evoked by exchanging the bath with 
Mg2+-free HHSS containing 10 µM NMDA and 200 µM glycine for 60 s. After background 
subtraction, the 340 and 380 nm image pairs were converted to [Ca2+]i using the formula 
[Ca2+]i = Kdβ(R-Rmin)/(Rmax –R) (Grynkiewicz et al., 1985). The dissociation constant (Kd) 
for fura-2 was 145 nM. β is the ratio of fluorescence intensity acquired with 380 nm 
excitation measured in Ca2+-free buffer (1 mM EGTA) and buffer containing saturating 
Ca2+ (5 mM). R is the fluorescence intensity ratio of images collected at 340 nm and 380 
nm excitation. Rmin, Rmax, and β were determined in a series of calibration experiments on 
intact cells. Rmin and Rmax values were generated by applying 10 M ionomycin in Ca2+-
free buffer (1 mM EGTA) and saturating Ca2+ (5 mM), respectively. Values for Rmin, Rmax, 
and β were 0.37, 9.38, and 6.46, respectively. These calibration constants were applied 
to all experimental recordings. The neuronal cell body was selected as the region of 
interest for all recordings. All neurons within the imaging field were included in the analysis 
and no exclusions were made. An individual sample (n=1) was defined as the average 
change in [Ca2+]i from all the neurons imaged on a single coverslip. 
 
Treatments 
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In synaptic imaging experiments an initial image (t = 0 h) was collected then HIV 
gp120 and drug treatments were applied directly to the cell culture media. When present, 
JZL184, IL-1ra, and AH6809 were added 15 min prior to addition of gp120. Selective CB 
receptor inverse agonists/antagonists were applied 5 min prior to the addition of JZL184. 
The cells were then returned to the cell culture incubator for 24 h. A second image (t = 24 
h) of the same field was collected and the change in the number of synapses presented 
as a percentage of the initial puncta count. For [Ca2+]i imaging experiments HIV gp120, IL-
1β and drug treatments were applied directly to the cell culture media. JZL184, IL-1ra, and 
AH6809 were added 15 min prior to addition of gp120 or IL-1β.  [Ca2+]i responses were 
evoked by superfusing 10 µM NMDA and 200 µM glycine for 60 s. 
 
Immunocytochemistry 
Hippocampal cultures were transfected with PSD95.FingR-eGFP after 11 days in 
vitro as described above. 48 h after transfection, cells were washed with PBS and then 
fixed with 4% paraformaldehyde for 10 min. Cells were then washed with PBS three times 
and permeabilized with 0.2% Triton X-100 (Sigma, St. Louis, MO, USA) for 10 min. Cells 
were blocked in 10% BSA and 0.2% Triton X-100 for 30 min at room temperature with 
slow shaking. After blocking, cells were incubated with mouse anti-Bassoon monoclonal 
antibody (1:200, Enzo Life Sciences, Farmingdale, NY, USA) in blocking buffer at 4 °C 
overnight. Cells were then washed 3 times with PBS and incubated with 
tetramethylrhodamine (TRITC)-conjugated goat anti-mouse antibody (1:500; Millipore, 
Billerica, MA, USA) in blocking solution at room temperature for 1 h. Cells were imaged 
after three washes. PSD95.FingR-eGFP was excited at 488 nm and emission was 
collected from 500 to 550 nm. TRITC was excited at 561 nm and emission was collected 
from 570 nm to 620 nm. 
 
ELISA 
Secreted PGE2 levels in the culture media were determined using a commercially 
available PGE2 ELISA kit (catalog number: ADI-930-001; Enzo Life Sciences, 
Farmingdale, NY, USA). Each sample was from a single well of a 6-well plate. Two 
reactions for each sample were run in parallel and averaged (n=1). The assays were 
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performed according to the manufacturer’s instructions. Absorbance was read at 405 nm 
using an Infinite M1000 PRO Microplate Reader (Tecan, Männedorf, Switzerland). 
 
Quantitative Reverse Transcription Real-Time PCR (qRT-PCR) 
RNA was extracted from cultures grown in 6-well plates using a commercially 
available RNA extraction kit (RNeasy Plus Mini Kit; catalog number: 74134; QIAGEN, 
Hilden, Germany), according to the manufacturer’s instructions. Each sample was 
collected from 3 wells under the same treatment. For qRT-PCR, a SuperScript III Platinum 
SYBR Green One-Step qPCR Kit (catalog number: 11746; Invitrogen, Carlsbad, CA, USA) 
was used following the manufacturer’s recommendations with minor modifications. Briefly, 
for each reaction, 5 uL of SYBR Green Reaction Mix with ROX was mixed with 0.2 uL 
Taq, 1 uL extracted RNA (containing 40-50 ng RNA), 0.2 uL primers (to make a final 
concentration 200 nM). The reaction was performed using a StepOnePlus Real-Time PCR 
System (ThermoFisher Scientific, Minneapolis, MN, USA). Synthesis of cDNA (50 °C for 
3 min) was immediately followed by PCR amplification (95 °C for 5 min, followed by 40 
cycles of 95 °C for 15 s and 60 °C for 1 min). IL-1β cDNA was amplified using the following 
primers: 5’-TCCTTGTGCAAGTGTCTGAAG-3’ and 5’-GTCTGTCAGCCTCAAAGAACA-
3’ (IDT Integrated DNA Technologies, Coralville, IA, USA). Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as internal reference using the following primers: 5’-
AATGGTGAAGGTCGGTGTG-3’ and 5’-GTGGAGTCATACTGGAACATGTAG-3’ (IDT 
Integrated DNA Technologies, Coralville, IA, USA). For each sample, two IL-1β reactions 
and two GAPDH reactions were run in parallel and averaged (n=1). Quantitative analysis 
was performed using the 2-ΔΔCt method. 
 
Statistics 
All data are presented as mean ± SEM. For all treatment groups, there were at 
least 6 samples. Data were first tested for unequal variance using Levene’s test (OriginPro 
v8.5, Northampton, MA, USA); no samples were found to be of unequal variance. For data 
sets with multiple comparisons a one-way or two-way ANOVA was performed. If gp120 
treatment exerted a significant interaction with other treatment groups, or if only one 
treatment (gp120 alone) was used, statistical significance was determined using one-way 
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ANOVA with a Tukey’s post-hoc test (Prism, GraphPad 5, La Jolla, CA 92037 USA). Time 
course data were analyzed with a repeated measures ANOVA using R under Rcmdr 
(Baier and Neuwirth, 2007). 
III. Results 
JZL184 inhibits rat MGL enzyme activity but not FAAH activity 
JZL184 completely inhibits MGL in mouse brain cultures at a concentration of 1 
µM (Grabner et al., 2016).  Here we tested the effects of JZL184 on rat hippocampal 
cultures. Mixed cultures containing neurons, astrocytes and microglia were treated with 
various concentrations of JZL184 for 24 h, the cells were lysed and an enzyme assay 
performed on isolated membranes (Figure 2.1A).  JZL184 inhibited the degradation of the 
colorimetric substrate 4-NPA with an IC50 of 0.22 ± 0.06 µM (Figure 2.1B). A concentration 
of 1 µM produced maximal inhibition, consistent with previous studies (Grabner et al., 
2016), and was used for subsequent experiments. 
This concentration of JZL184 did not significantly influence the activity of fatty acid 
amide hydrolase (FAAH) (Figure 2.1C and D). Cultures were treated for 24 h with 1 µM 
JZL184 or 1 µM JZL195, a potent inhibitor of FAAH and MGL. Cells were lysed and FAAH 
enzymatic activity assessed by measuring the degradation of the fluorogenic substrate, 
arachidonoyl-AMC.  Thus, the 1 µM concentration of JZL184 used in these studies is 
selective for MGL relative to FAAH. 
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Figure 2.1 JZL184 inhibits MGL enzyme activity but not FAAH activity. (A) 
Representative traces show MGL enzymatic activity during incubation with the colorimetric 
substrate, 4-NPA. Cultures were treated for 24 h with 0, 0.3 or 1 µM JZL184. Cells were 
lysed and incubated with 4-NPA as described in Materials and Methods. Absorbance was 
monitored every 5 min for 180 min and presented as relative absorbance units (RAU) 
normalized to µg protein.  (B) Plot shows concentration dependent inhibition of MGL 
activity by JZL184.  Enzyme activity was determined from the linear phase of the reaction 
(15-55 min in A).  The concentration response curve was generated using a nonlinear, 
least-squares curve fitting program (Origin 6.0, OriginLab Corp.) to fit  a logistic equation 
of the form % of Control  = [(A1 – A2)/(1 + (X/IC50)p)]+A2 where X = drug concentration, IC50 
= 219  62 nM, A1 = 95 ± 3 % inhibition without drug, A2 = 65 ± 2 % inhibition at a maximally 
effective drug concentration and p = 3 ± 2 slope factor.  Values are expressed as mean ± 
SEM from 5 separate enzyme assays.  The incomplete inhibition produced by a maximal 
concentration of JZL184 is due to the hydrolysis of 4-NPA by lipid hydrolases other than 
MGL present in the crude membrane preparation isolated from neuronal cell cultures.  (C) 
Representative traces show FAAH enzymatic activity during incubation with the 
fluorogenic substrate, arachidonoyl-AMC. Cultures were treated for 24 h with 1 µM JZL184 
or 1 µM JZL 195, a potent inhibitor of FAAH and MGL. Cells were lysed and incubated 
with arachidonoyl-AMC as described below.  Fluorescence was monitored every 5 min for 
200 min and presented as relative fluorescence units (RFU) normalized to µg protein. (D) 
Bar graph summarizes FAAH activity relative to untreated cultures (control) during the 
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linear phase of the reaction (0-75 min). FAAH activity in the presence of JZL184 was not 
significantly different from control. *p<0.05 relative to control (one-way ANOVA with 
Tukey’s post-test, n=6). 
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PSD95.FingR-eGFP labels functional synapses 
The HIV-1 envelope protein gp120 is a potent neurotoxin in vitro that mimics the 
synapse loss observed in HAND via a neuroinflammatory mechanism (Kim et al., 2011; 
Mishra et al., 2012). Here we examined the effects of inhibiting MGL with JZL184 on 
synapse loss induced by gp120 and assessed the mechanism of action. To monitor 
changes in the number of synapses, rat hippocampal cultures were transfected with 
expression plasmids for a recombinant antibody-like protein, PSD95.FingR-eGFP, and 
tdTomato, as previously described (Gross et al., 2013). Transfected cells were imaged 
using a laser scanning confocal microscope as described in Methods. The PSD95.FingR-
eGFP construct expressed a GFP-tagged fibronectin intrabody that specifically bound to 
the endogenous postsynaptic scaffolding protein PSD95, labelling glutamatergic 
synapses in a punctate pattern (Figure 2.2A). The red tdTomato protein filled the 
cytoplasm enabling visualization of the transfected cell’s morphology. This method was 
previously shown to label functional synapses without interfering with normal synaptic 
function. In extensive characterization experiments Gross et al. (2013) showed that 
PSD95.FingR-eGFP expressed in primary neuronal cultures co-immunoprecipitated with 
native PSD-95, that the eGFP puncta co-localized with PSD-95 immunoreactivity, and that 
siRNA knock down of endogenous PSD-95 produced a comparable knockdown of 
PSD95.FingR-eGFP labelling.  Here, we used immunocytochemistry to confirm that green 
fluorescent puncta labelled synaptic structures.  Immunoreactivity for the presynaptic 
scaffolding protein Bassoon co-localized with PSD95.FingR labeled postsynaptic sites 
(Figure 2.2B). 83 ± 1 % (n=5) of the green fluorescent puncta co-localized with Bassoon 
immunoreactive puncta. To track individual synapses in live cells, image stacks 
compressed in the z dimension were processed using an algorithm that counted green 
fluorescent puncta that met size (area between 0.13 µm2 and 0.86 µm2) and intensity 
criteria, and were in contact with a binary mask derived from the red tdTomato image. This 
method enabled the same neuron to be imaged before and after treatment to measure 
changes in the number of synapses. 
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Figure 2.2 PSD95.FingR-eGFP (Intrabody) labels postsynaptic terminals at 
excitatory synapses. (A) Representative confocal images of a neuron expressing 
PSD95.FingR-eGFP and tdTomato were acquired and processed as described in 
Methods. PSD95.FingR-eGFP puncta were identified by filtering compressed z-stacks (8 
µm) of confocal images. All puncta that met size (between 0.13-0.86 µm2) and intensity 
criteria, and were in contact with a binary mask derived from the tdTomato image were 
counted as synapses. Puncta were dilated and overlaid on the tdTomato maximum 
projection (Processed) for display purposes. Insets are enlarged images of the boxed 
regions. Scale bars represent 10 µm. (B) Representative confocal images of a neuron 
expressing PSD95.FingR-eGFP (green) and immunolabeled for Bassoon (red). 
PSD95.FingR-eGFP puncta co-localized with Bassoon immunoreactivity (yellow, 
Merged). Note that non-transfected cells were also present in the field, and thus not all 
Bassoon immunoreactive puncta (red) co-localized with PSD95.FingR-eGFP (green) 
puncta. Insets are enlarged images of the boxed regions. Scale bars represent 10 µm. 
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gp120-induced synapse loss was blocked by inhibition of MGL 
Treating hippocampal neurons in culture with the HIV-1 envelope protein gp120IIIB 
induces the loss of synaptic connections via a mechanism that requires microglial 
production of the inflammatory cytokine IL-1β (Kim et al., 2011). Treating the culture with 
600 pM gp120 for 24 h produced a 15 ± 3% loss of PSD95.FingR labeled postsynaptic 
sites (Figure 2.3A). Synapse loss was maximal by 24 h and it persisted for 48 h (Figure 
2.3A).  The time course of gp120 induced synapse loss shown here is in good agreement 
with previous studies using a PSD95-GFP fusion protein to report glutamatergic synapses 
(Kim et al., 2011).  Advantages of the intrabody approach relative to imaging the 
expressed fusion protein are that the intrabody construct incorporates a transcriptional 
control mechanism to reduce the expression of excess intrabody, reducing background 
fluorescence, and intrabody expression does not drive increased synapse formation as 
does the PSD95-GFP fusion protein. 
To determine whether altering endocannabinoid tone would modulate the process 
of gp120-induced synapse loss, we examined the effects of inhibiting the breakdown of 
the endocannabinoid 2-AG to AA and glycerol by MGL. Inhibition of MGL has been shown 
to suppress neuroinflammation induced by neurotoxins (Nomura et al., 2011; Viader et al., 
2015; Grabner et al., 2016). To determine whether inhibition of MGL could attenuate 
gp120-induced synapse loss, the cultures were treated with the selective MGL inhibitor, 
JZL184, 15 min prior to and during exposure to gp120 (Figure 2.3B and C). JZL184 (1 µM) 
treatment completely blocked synapse loss induced by 24 h exposure to 600 pM gp120, 
suggesting that inhibition of MGL protects synapses from gp120-induced loss (Figure 2.3B 
and C). JZL184 alone did not affect the number of synapses. 
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Figure 2.3 HIV gp120-induced loss of synapses and IL-1β expression were blocked 
by inhibition of MGL. (A) Graph shows time-dependent changes in the number of 
PSD95.FingR-eGFP puncta for untreated cells (control, circles) and cells treated with 600 
pM gp120 (gp120, squares). Data are expressed as mean ± SEM. Repeated measures 
ANOVA revealed gp120 by time interactions [F3, 35 = 6.25, p<0.01].  *p<0.05, **p<0.01 
relative to control at the same time-point (Tukey’s post-test, n = 7). (B) Bar graph 
summarizes changes in PSD95.FingR-eGFP puncta after 24 h treatment under control 
conditions (open bars) in the absence (n = 8) or presence (n = 6) of 1 µM JZL184 or treated 
with 600 pM gp120 (solid bars) in the absence (n = 7) or presence (n = 6) of JZL184. 
JZL184 was added 15 min prior to gp120 for all experiments. Data are expressed as mean 
± SEM. *p<0.05 relative to untreated control, #p<0.05 relative to untreated gp120 (one-
way ANOVA with Tukey’s post-test). (C) Representative processed images of neurons 
with no treatment (control), or treated with 600 pM gp120 in the absence or presence of 1 
µM JZL184 for 24 h. The insets are enlarged images of the boxed region. Scale bars 
represent 10 µm. (D) Bar graph summarizes IL-1β mRNA expression relative to control (n 
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= 12) after treatment with 600 pM gp120 and in the absence (n = 18) or presence of 1 µM 
JZL184 (n = 16) for 4 h. Data are expressed as mean ± SEM. **p<0.01 relative to control, 
##p<0.01 relative to gp120 treated group (one-way ANOVA with Tukey’s post-test). 
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JZL184 blocks gp120-induced IL-1β production 
We next studied the effects of JZL184 on gp120-induced IL-1β production. In a 
previous study we showed that gp120 evoked the secretion of IL-1β protein, detected by 
ELISA, and increased the expression of IL-1β mRNA, detected by qRT-PCR (Kim et al., 
2011). Here, we used the qRT-PCR assay because of its higher sensitivity. Gp120-
induced increases in IL-1β mRNA levels were measured in the absence and presence of 
JZL184 to determine whether inhibition of MGL suppressed IL-1β production. Figure 3D 
shows that 4 h treatment with 600 pM gp120 increased the expression of IL-1β mRNA by 
2.0 ± 0.2-fold. This increase was significant and completely blocked by treatment with 
JZL184 (1 µM). These results suggest that inhibition of MGL decreases IL-1β production 
which might contribute to the protection from gp120-induced synapse loss afforded by 
JZL184. 
 
JZL184 blocks gp120-induced potentiation of NMDA-evoked Ca2+ influx 
The HIV protein Tat and the inflammatory cytokine IL-1β potentiate NMDARs by 
activating Src family tyrosine kinases (Viviani et al., 2003; Krogh et al., 2014), which are 
known to phosphorylate NMDARs resulting in potentiated currents (Yu and Salter, 1999). 
Synapse loss induced by gp120 requires activation of NMDARs (Kim et al., 2011). Here 
we determined whether exposure to gp120 would increase the amplitude of NMDA-
evoked changes in [Ca2+]i. Fura-2-based [Ca2+]i imaging was performed as described in 
Methods. Cells were superfused with HEPES Hank’s salt solution (HHSS) at a flow rate 
of 2 mL min-1 for 60 s and then the bath was exchanged to Mg2+-free HHSS containing 
200 µM glycine and 10 µM NMDA for 60 s. As shown in Figure 4A, NMDA evoked a 
transient increase in the [Ca2+]i that rose from a mean basal level of  68 ± 3 nM to peak at 
241 ± 25 nM in control cells (t = 0 h).  Treatment with 600 pM gp120 produced a time-
dependent increase in the amplitude of the NMDA-evoked response (Figure 2.4A and B).  
The gp120-induced potentiation of the NMDA-evoked response peaked after 4 h exposure 
to gp120 and then adapted.  This time course is consistent with potentiated NMDA-
mediated Ca2+ influx driving cellular adaptations such as synapse loss (Figure 2.3A) and 
downregulation of NMDAR-mediated synaptic currents (Green and Thayer, 2016).  The 
net NMDA-evoked [Ca2+]i response was increased by 113 % in cells treated for 4 h with 
600 pM gp120 relative to control cells (Figure 2.4C). In the presence of IL-1ra (1 µg mL-1), 
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an IL-1 receptor antagonist, the gp120-induced potentiation was significantly reduced 
(Figure 2.4D). This result is consistent with gp120 evoking the release of IL-1β from 
microglia; the released IL-1β then activates IL-1 receptors on neurons leading to 
potentiation of NMDARs. If JZL184 inhibited synapse loss by reducing the production of 
IL-1β as suggested by the qRT-PCR data shown in Figure 2.3D, we would expect JZL184 
to prevent gp120-induced potentiation of NMDARs but not necessarily potentiation 
induced by direct application of IL-1β. As shown in Figure 2.4E and F, 1 µM JZL184 
completely blocked the gp120-induced potentiation of the NMDA-evoked increase in 
[Ca2+]i. If the effects of JZL184 were mediated entirely by decreased production of IL-1β, 
then direct application of IL-1β to the culture should potentiate NMDA receptors in manner 
insensitive to inhibition of MGL. As shown in Figure 2.4G and H, treating the culture with 
IL-1β for 4 h potentiated the amplitude of the NMDA evoked [Ca2+]i increase. In this cohort 
of cells NMDA increased the [Ca2+]i in untreated cells from a mean level of 41 ± 3 nM to 
peak at 458 ± 28 nM.  The net NMDA-evoked [Ca2+]i response increased by 60 % in cells 
treated with 3 ng mL-1 IL-1β for 4 h. As hypothesized, treatment with 1 µM JZL184 together 
with IL-1β for 4 h did not significantly affect the IL-1β-induced potentiation of the NMDA-
evoked [Ca2+]i response. Thus, JZL184 blocks gp120-induced IL-1β production preventing 
potentiation of NMDARs. 
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Figure 2.4 Inhibition of MGL suppresses gp120-induced potentiation of NMDA 
receptors by blocking IL-1β production. (A-B) HIV-1 gp120-induced a biphasic change 
in NMDA-evoked [Ca2+]i responses. (A) representative traces show NMDA-evoked [Ca2+]i 
(10 M x 60 s) increases from a control neuron (0 h) or neurons treated with 600 pM gp120 
for the times indicated above the traces. (B) plot summarizes NMDA-evoked [Ca2+]i 
responses after treatment with gp120  for 0 to 48 h. Data are expressed as mean ± SEM.  
**p<0.01 relative to 0 h time-point, ##p<0.01 relative to 4 h time-point (ANOVA with 
Tukey’s post-test, n ≥ 6). (C) Representative traces show increase in [Ca2+]i evoked by 
application of 10 µM NMDA (60s) to control neurons and neurons treated with 600 pM 
gp120 for 4 h in the absence and presence of 1 µg mL-1 IL-1ra.  IL-1ra was added 15 min 
before gp120. (D) Bar graph summarizes net [Ca2+]i increase (Δ[Ca2+]i) evoked by 10 µM 
NMDA for control and neurons treated with 600 pM gp120 for 4 h in the absence and 
presence of 1 µg mL-1 IL-1ra. ***p<0.001 relative to untreated control; ###p<0.001 relative 
to gp120 only treatment (one-way ANOVA with Tukey’s post-test, n=16). (E) 
Representative traces show increase in [Ca2+]i evoked by application of 10 µM NMDA 
(60s) to control neurons and neurons treated with 600 pM gp120 for 4 h in the absence 
and presence of 1 µM JZL184. JZL184 was added 15 min before gp120. (F) Bar graph 
summarizes Δ [Ca2+]i evoked by 10 µM NMDA for control neurons in the absence (n=10) 
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and presence (n=6) of 1 µM JZL184 and neurons treated with 600 pM gp120 for 4 h in the 
absence (n=13) and presence (n=11) of 1 µM JZL184. **p<0.01 relative to untreated 
control; #p<0.05, relative to the group only treated with gp120 (one-way ANOVA with 
Tukey’s post-test). (G) Representative traces show NMDA-evoked increase in [Ca2+]i for 
control neurons and neurons treated with 3 ng mL-1 IL-1β for 4 h in the absence or 
presence of 1 µM JZL184. JZL184 was added 15 min before IL-1β. (H) Bar graph shows 
Δ [Ca2+]i evoked by 10 µM NMDA for control neurons in the absence (n=17) and presence 
(n=10) of 1 µM JZL184 and neurons treated with 3 ng mL-1 IL-1β for 4 h in the absence 
(n=20) and presence of 1 µM JZL184 (n=19). ***p<0.001 relative to untreated control, 
††p<0.01 relative to JZL184 treated control (one-way ANOVA with Tukey’s post-test). 
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JZL184 activated CB2Rs blocks gp120-induced synapse loss 
JZL184 could prevent gp120-induced synapse loss by activating cannabinoid 
receptors secondary to the accumulation of 2-AG and/or its neuroprotective effects could 
result from reduced PG production as a result of decreased conversion of 2-AG to AA 
(Nomura et al., 2011; Ueda et al., 2011; Blankman and Cravatt, 2013). To determine 
whether the protective effect of JZL184 resulted from increased 2-AG that subsequently 
activated CB2R, we examined the effects of JZL184 on gp120-induced synapse loss in 
the absence and presence of 100 nM AM630, a selective CB2R inverse agonist/antagonist. 
We have shown previously that this concentration of AM630 selectively and completely 
blocks CB2R function in rat hippocampal cultures (Kim et al., 2011).  AM630 (100 nM) 
reversed the effect of JZL184 and restored the synapse loss-induced by gp120 (Figure 
2.5A). We confirmed that the effect of JZL184 was mediated CB2R using another 
structurally distinct CB2R inverse agonist/antagonist. SR144528 has been shown 
previously to selectively block CB2R at a concentration of 100 nM (Dhopeshwarkar and 
Mackie, 2016).   As shown in Figure 5B, SR144528 completely blocked the effects of 
JZL184. AM630 and SR144528 alone produced 8 ± 6 % and 3 ± 5 % change in synapses, 
respectively, which is not significantly different from control. In contrast, treatment with 
rimonabant, a CB1R inverse agonist/antagonist that we have shown previously to 
selectively and completely block CB1R function in rat hippocampal cultures (Roloff and 
Thayer), did not affect JZL184-mediated protection (Figure 2.5C).  Similarly, the 
structurally distinct CB1R inverse agonist/antagonist LY320135, at a concentration of 1 
µM, which has been shown previously to selectively inhibit CB1R function (Felder et al., 
1998), also failed to affect JZL184-mediated protection (Figure 2.5D).  Thus, the effects 
of JZL184 were not through activation of CB1R. Rimonabant and LY320135 alone 
produced -2 ± 9 % and 9 ± 6 % change in synapses, respectively, which is not significantly 
different from control. JZL184 suppression of IL-1β mRNA expression was partially 
reversed by AM630 (100 nM) (Figure 2.5E). In the presence of both JZL184 and AM630, 
gp120-evoked IL-1β production was significantly less than that evoked by gp120 alone. 
Additionally, in cells treated with both JZL184 and AM630, gp120-evoked IL-1β production 
was significantly greater than that evoked by gp120 in the presence of JZL184.  AM630 
alone had no effect on IL-1β mRNA level (1.1 ± 0.2 -fold induction). These results suggest 
that JZL184 attenuates gp120-induced synapse loss, in part, through activation of CB2R 
and subsequent suppression of IL-1β production.  
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Figure 2.5 Activation of CB2R but not CB1R was required for JZL184 inhibition of 
gp120-induced neurotoxicity. (A) Bar graph shows changes in PSD95.FingR-eGFP 
puncta number after 24 h treatment with the indicated treatment groups: untreated (n=12), 
600 pM gp120 (n=16), gp120 + 1 µM JZL184 (n=9), and gp120 + JZL184 + 100 nM AM630 
(n=8). The CB2R inverse agonist/antagonist AM630 was added 5 min prior to JZL184. 
***p<0.001 relative to untreated, #p<0.05 relative to the group only treated with gp120, 
†p<0.05 relative the group treated with gp120 + JZL184 (one-way ANOVA with Tukey’s 
post-test).  (B) Bar graph shows changes in PSD95.FingR-eGFP puncta number after 24 
h treatment with the indicated treatment groups: untreated (n=10), 600 pM gp120 (n=10), 
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gp120 + 1 µM JZL184 (n=10), and gp120 + JZL184 + 100 nM SR144528 (n=10). The 
CB2R inverse agonist SR144528 was added 5 min prior to JZL184. **p<0.01 relative to 
untreated, ###p<0.001 relative to the group only treated with gp120, ††p<0.01 relative the 
group treated with gp120 + JZL184 (one-way ANOVA with Tukey’s post-test). (C) Bar 
graph shows changes in PSD95.FingR-eGFP puncta number after 24 h treatment with the 
indicated treatment groups: untreated (n=8), 600 pM gp120 (n=8), gp120 + 1 µM JZL184 
(n=7), and gp120 + JZL184 + 100 nM rimonabant (n=9). The CB1R inverse agonist 
rimonabant was added 5 min prior to JZL184. **p<0.01 relative to untreated; #p<0.05, 
##p<0.01 relative to the group only treated with gp120 (one-way ANOVA with Tukey’s 
post-test). (D) Bar graph shows changes in PSD95.FingR-eGFP puncta number after 24 
h treatment with the indicated treatment groups: untreated (n=9), 600 pM gp120 (n=8), 
gp120 + 1 µM JZL184 (n=9), and gp120 + JZL184 + 1 µM LY320135 (n=8). The CB1R 
inverse agonist LY320135 was added 5 min prior to JZL184. *p<0.05 relative to untreated; 
#p<0.05, ###p<0.001 relative to the group only treated with gp120 (one-way ANOVA with 
Tukey’s post-test). (E) Bar graph summarizes IL-1β mRNA expression measured using 
qRT-PCR assay after 4 h treatment with the indicated treatments: untreated (n=10), 600 
pM gp120 (n=13), gp120 + 1 µM JZL184 (n=9), and gp120 + JZL184 + 100 nM AM630 
(n=9). AM630 was added 5 min prior to JZL184.  ***p<0.001 relative to untreated group, 
#p<0.05 relative to the group only treated with gp120, †p<0.05 relative to the group treated 
with gp120 and JZL184 (one-way ANOVA with Tukey’s post-test). 
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JZL184 suppresses gp120-induced PGE2 production 
Because AM630 only partially reversed JZL184 inhibition of gp120-induced IL-1β 
expression, JZL184 might protect synapses through a mechanism in addition to activation 
of CB2R. A potential role for reduced PG production in the protection of synapses was 
considered because JZL184 decreases the conversion of 2-AG to AA which is the 
precursor for PGs (Nomura et al., 2011). PGE2 contributes to neuroinflammation 
(Johansson et al., 2013; Johansson et al., 2015); thus, we first determined whether gp120 
treatment can induce the production of PGE2. Treatment with 600 pM gp120 stimulated 
PGE2 production and this effect was blocked in the presence of 1 µM JZL184 (Figure 2.6A). 
PGE2 (56 ± 5 pg mL-1) was present in media from untreated cultures.  Treatment (4 h) with 
HIV gp120 increased PGE2 to 80 ± 7 pg mL-1.  Note that PGE2 levels were measured in 
the relatively large volume of the cell culture well and might be higher in the cell monolayer. 
To determine whether PGE2 contributed to gp120-induced synapse loss we examined 
the effects of gp120 in the absence and presence of AH6809, an antagonist for 
prostaglandin 1 and 2 receptors (EP1-2R)  (Woodward et al., 1995). Gp120-induced 
synapse loss was blocked completely by 10 µM AH6809 (Figure 2.6B). Thus, activation 
of EP1-2Rs by PGs is necessary for gp120-induced synapse loss. However, the inhibition 
of gp120-induced IL-1β expression by 10 µM AH6809 was incomplete (Figure 2.6C), 
suggesting that PGs might also act downstream of IL-1β to facilitate synapse loss (Figure 
2.7B, green arrows). AH6809 alone had no effect on IL-1β mRNA levels (1.0 ± 0.08 fold 
change). This is consistent with a previous report showing synapse loss induced by the 
direct application of IL-1β requires PGE2 production (Mishra et al., 2012). Furthermore, 
calcium imaging experiments showed that IL-1β-induced potentiation of NMDA receptors 
was not blocked by AH6809 (Figure 2.6D). These data indicate that the PG pathway 
downstream of IL-1β is separate from that mediating the potentiation of NMDA receptors 
(Figure 2.7B). Thus, activation of PG receptors is required for gp120-induced synapse 
loss (Figure 2.6B). These results suggest that, in addition to preventing synapse loss 
through 2-AG activation of CB2R (Figure 2.5), JZL184 inhibition of PGE2 production could 
also reduce IL-1β production (Figure 2.6C) and exert downstream actions such as an 
inhibition of PG-induced glutamate release. 
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Figure 2.6 MGL inhibition blocks gp120-induced PGE2 production. EP1-2R activation 
is required for synapse loss and IL-1β expression. (A) Bar graph shows changes in 
PGE2 levels in culture media measured using ELISA. PGE2 levels are shown for control 
conditions in the absence (n=14) or presence of 1 µM JZL184 (n=9) and after treatment 
with 600 pM gp120 for 4 h in the absence (n=17) or presence (n=14) of 1 µM JZL184. 
*p<0.05 relative to untreated control, #p<0.05 relative to the group only treated with gp120 
(one-way ANOVA with Tukey’s post-test). (B) Bar graph shows changes in the number of 
PSD95.FingR-eGFP puncta under control conditions in the absence (n=11) or presence 
(n=6) of 10 µM AH6809, an EP1-2R antagonist, or 24 h following treatment with 600 pM 
gp120 in the absence (n=9) or presence (n=9) AH6809. **p<0.01 relative to untreated 
control, #p<0.05 relative to the group treated with gp120 alone (one-way ANOVA with 
Tukey’s post-test). (C) Bar graph summarizes changes of IL-1β mRNA expression in 
untreated cultures (n=10) and after 4 h treatment with 600 pM gp120 in the absence (n=11) 
or presence (n=10) of 10 µM AH6809. Data are expressed as fold induction relative to 
untreated group. *p<0.05, **p<0.01 relative to untreated group; #p<0.05 relative to the 
group treated with gp120 alone (one-way ANOVA with Tukey’s post-test). (D) Bar graph 
shows Δ[Ca2+]i evoked by 10 µM NMDA for control cells in the absence (n=7) and 
presence (n=6) of 10 µM AH6809 and neurons treated with 3 ng mL-1 IL-1β for 4 h in the 
absence (n=11) and presence (n=8) of AH6809. ***p<0.001 relative to untreated control, 
†p<0.05 relative to AH6809 treated control (one-way ANOVA with Tukey’s post-test). 
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IV. Discussion 
Chronic neuroinflammation underlies the pathogenesis of HAND (Sodhi et al., 
2004; Saylor et al., 2016). Infected immune cells release viral proteins and inflammatory 
factors which act on microglia, astrocytes, and neurons to produce the synaptodendritic 
damage that correlates with cognitive decline in HIV infected patients (Ellis et al., 2007). 
Here we used a simplified in vitro model to study the interaction of the eCB system with 
the neuroinflammatory response evoked by the HIV envelope protein. HIV gp120 induced 
synapse loss, a hallmark of HAND, by activating microglia to release IL-1β that then 
potentiated NMDA receptor function (Viviani et al., 2006; Kim et al., 2011). Inhibiting the 
metabolism of the eCB, 2-AG, attenuated gp120-induced synapse loss via activation of 
CB2R and may have also protected synapses via reduced PG production. These pathways 
are summarized in Figure 2.7. 
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Figure 2.7 Summary scheme shows the hypothesized mechanism of the synapse 
protection induced by the inhibition of MGL.  (A) Diagram illustrates the JZL184-
induced increase in 2-AG that activates CB2R-dependent synapse protection and the 
reduced AA production that decreases PGE2-mediated synapse loss.  (B) Scheme shows 
2-AG and AA dependent pathways affected by JZL184 to reduce synapse loss. Solid 
arrows indicate flow of signaling pathways.  Green lines highlight prostaglandin signaling 
and red lines highlight eCB signaling. 
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The suppression of gp120-induced synapse loss described here is the first report 
of a CB2R-mediated effect of JZL184 on neuroinflammation induced synaptic damage. 2-
AG is one of the most abundant eCBs in the brain and is a full agonist at both CB1R and 
CB2R (Gonsiorek et al., 2000). MGL is the primary enzyme responsible for 2-AG hydrolysis 
in brain, accounting for 85% of its metabolism (Blankman et al., 2007). Pharmacological 
and genetic inactivation of MGL has been shown to significantly increase brain 2-AG levels 
(Long et al., 2009; Grabner et al., 2016). Thus, the accumulation of 2-AG in the presence 
of JZL184 is expected. However, the relative contribution of increased 2-AG versus 
decreased AA following inhibition of MGL has varied in different models.  In the mouse 
experimental autoimmune encephalitis model, inhibition of MGL reduced symptoms via a 
CB1R/CB2R mechanism (Brindisi et al., 2016). Blocking MGL suppresses LPS-induced 
neuroinflammation and loss of dopamine neurons in a model of Parkinson’s disease by 
decreasing PG production with no evidence for enhanced eCB signaling (Nomura et al., 
2011). Similarly, in transgenic mouse models of Alzheimer’s disease JZL184 was 
neuroprotective but, without clear involvement of CB receptors (Chen et al., 2012; Piro et 
al., 2012).  In mice, JZL184 increased brain 2-AG 8-fold and elicited an array of CB1R-
mediated behavioral effects (Long et al., 2009). The principal conclusion from the studies 
described in this report is that CB2R activation following inhibition of MGL affords 
significant protection from synapse loss induced by gp120. 
There are several aspects of gp120-induced synapse loss that might render it 
particularly susceptible to CB2R activation. In a previous report, we showed that the CB1/2R 
agonist WIN55,212-2 blocked gp120-induced IL-1β production and synapse loss through 
activation of CB2Rs on microglia (Kim et al., 2011). Perhaps gp120 activation of the 
CXCR4 pathway to trigger IL-1β release from microglia is particularly sensitive to inhibition 
by CB2R activation. CB2R agonists have been shown to inhibit chemokine CXCL12-
induced and CXCR4-mediated chemotaxis of T lymphocytes (Ghosh et al., 2006). The 
neuroprotective effects of JZL184 in transgenic models of Alzheimer’s disease appear to 
result from activation of peroxisome proliferator-activated receptor-γ and decreased PG 
activation of NF-κB resulting in reduced expression of β-secretase and decreased Aβ 
production, a pathway not expected to be regulated by CB receptors (Piro et al., 2012; 
Zhang et al., 2014). Responses in microglia evoked by LPS activation of the toll-like 
receptor 4 pathway are inhibited by CB2R agonists (Romero-Sandoval et al., 2009; Oh et 
al., 2010; Merighi et al.; Ma et al., 2015; Malek et al., 2015) although, there are reports of 
non-receptor mediated effects of CBs (Puffenbarger et al., 2000; Tham et al., 2007) and 
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a lack of CB2R effects in some studies (Kouchi, 2015). The failure of CB2R to contribute 
to the anti-inflammatory effect of JZL184 in vivo may result from receptor desensitization 
following the prolonged treatment protocols used for in vivo studies (Nomura et al., 2011). 
Indeed, prolonged administration of JZL184 desensitizes CB1R (Schlosburg et al., 2010). 
However, desensitization of the CB2Rs that mediate the effect described here has not 
been explicitly shown, in part because the expression of CB2Rs is upregulated by 
inflammatory stimuli (Benito et al., 2008). In acute models of peripheral inflammatory pain, 
JZL184 produces analgesia via CB1 and CB2 receptors (Guindon et al., 2011). Thus, 
JZL184 may reduce neuroinflammation by PG and/or eCB mechanisms depending on the 
specific inflammatory stimulus and duration of treatment. 
In the brain, hydrolysis of 2-AG by MGL is the primary source of AA for conversion 
to PGs by cyclooxygenase (Nomura et al., 2011). PGE2 production is required for IL-1β-
evoked synapse loss (Mishra et al., 2012). Here, we tested whether decreased PG levels 
contributed to the synapse protective effects of JZL184. Activation of EP1-2Rs was 
necessary for gp120-induced synapse loss and JZL184 blocked gp120-induced PGE2 
production. Thus, it is likely that JZL184 suppression of PGE2 production contributed to 
the protective effect. However, because AM630 completely blocked the synapse 
protection afforded by JZL184, we conclude that the reduction in PG levels produced by 
MGL inhibition was not the primary mechanism in this model. JZL184 did not suppress the 
basal level of PGE2 present in unstimulated cultures, suggesting that sufficient PGE2 from 
a source other than MGL was available to enable gp120-induced synapse loss. 
Furthermore, IL-1β potentiated NMDA receptors independent of EP1-2R activation, 
suggesting separate IL-1β actions on PG production and NMDA receptor signaling.  A 
partial attenuation of gp120-evoked IL-1β production with the EP1-2R antagonist can be 
reconciled with its complete block of gp120-induced synapse loss by considering the PG 
regulation of synapse loss at two steps in the pathway activated by gp120. Activation of 
EP1-2Rs facilitates glial production of IL-1β and stimulates glutamate release resulting in 
biochemical potentiation of NMDARs and their direct activation, respectively (Mishra et 
al., 2012).  Thus, we cannot rule out a contribution resulting from decreased PGE2 
synthesis. The CB2R- and EP1-2R-depedence of JZL184 inhibition of IL-1β production were 
both partial effects, consistent with the idea that the inhibition of MGL has dual actions via 
CB2 receptor signaling and decreased PGE2 production. 
HIV-1 gp120 evoked synapse loss via a multi-step process (Figure 7) involving 
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multiple cell types. The primary effects of JZL184 appear to be on glia where activation of 
CB2R or reduced PGE2-dependent activation of EP1-2Rs inhibits the release of IL-1β. In a 
previous study we found that IL-1β induced PGE2 production was required for synapse 
loss, presumably via an EP1-2R mediated increase in presynaptic glutamate release 
(Mishra et al., 2012). If we consider a role for presynaptic glutamate release in gp120-
induced synapse loss, then we might expect a CB1R-mediated component to JZL184-
mediated synapse protection because 2-AG mediates a robust inhibition of excitatory 
synaptic transmission (Straiker et al., 2009; Roloff et al., 2010).  However, neither 
rimonabant nor LY320135 affected JZL184-mediated protection, suggesting that the 
elevation in 2-AG might be localized to a microdomain with preferential access to microglia 
independent of presynaptic terminals. 
Cannabinoid receptor agonists have beneficial effects in models of HAND (Kim et 
al., 2011; Avraham et al., 2014; Purohit et al., 2014). However, drugs that directly activate 
cannabinoid receptors might cause receptor desensitization during long-term treatment, 
diminishing the neuroprotective efficacy of the endocannabinoid system. Agonists with 
actions on CB1 receptors or those with low selectivity may have abuse liability. 
Alternatively, inhibition of MGL only potentiates endogenously produced 2-AG so that 
receptor activation is dependent on a stimulus. High doses of JZL184 produced extensive 
CB1 receptor activation (Long et al., 2009).  However, prolonged, low-dose JZL184 
treatment elicited an anti-inflammatory effect without producing CB1 receptor tolerance or 
cannabinoid dependence (Kinsey et al., 2013). Furthermore, because brain AA production 
is primarily dependent on MGL, in contrast to the gut, drugs that inhibit MGL can reduce 
brain PG levels without the gastrointestinal side effects produced by nonsteroidal anti-
inflammatory drugs (Scheiman, 2016). Thus, drugs that inhibit MGL show promise for 
reducing neuroinflammation in HAND. 
Dendritic damage and loss of synaptic connections correlate with cognitive decline 
in HAND patients. Synapse loss induced by HIV proteins occurs early and via a different 
signaling pathway from that leading to neuronal death (Kim et al., 2008b), suggesting that 
synapse loss might be a mechanism to reduce excitotoxicity (Hargus and Thayer, 2013). 
Indeed, synapse loss is reversible (Shin et al., 2012) and rescue of synapses lost following 
exposure to the neuroinflammatory HIV protein Tat restored cognitive function (Raybuck 
et al., 2017). Chronic inhibition of MGL in amyloid precursor protein transgenic mice 
induced recovery of synaptic spines and improvement of spatial learning and memory 
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function (Chen et al., 2012). Perhaps the synapse loss induced by the neuroinflammatory 
component of neurodegenerative diseases is readily reversible. It will be interesting to 
determine whether, in addition to protecting synapses from loss induced by HIV proteins, 
MGL inhibition by drugs such as JZL184 can rescue synapses when given after loss has 
already occurred. 
This report shows for the first time that pharmacological inhibition of MGL can 
afford neuroprotection via activation of CB2 receptors on brain microglia. This mechanism 
differs from other reports in which the reduced neuroinflammation produced by JZL184 
was primarily mediated via reduced PG signaling. The mechanism of protection afforded 
by MGL inhibitors may depend on the specific cell types involved in the neuroinflammatory 
response, the concentration and duration of drug treatment and the unique signaling 
pathways recruited in response to various inflammatory stimuli. This is the first report 
showing inhibition of MGL affords neuroprotection in a model of HAND, suggesting that 
the chronic neuroinflammation that underlies this disorder may be particularly susceptible 
to modulation of the eCB system. 
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I. Introduction 
HIV-associated neurocognitive disorder (HAND) affects about half of the over 36 
million people infected (Saylor et al., 2016). Although broad application of combination 
antiretroviral therapy (cART) has dramatically reduced the number of patients that 
progress to AIDS, cART does not eradicate HIV from the brain (Ellis et al., 2007; Saylor 
et al., 2016). Thus, the prevalence of HAND remains high, in part because of the increased 
lifespan of HIV infected individuals (Eggers et al., 2017). Currently there is no effective 
treatment for HAND. 
Chronic neuroinflammation is a major component of HAND pathogenesis (Chen et 
al., 2014; Gill and Kolson, 2014; Walsh et al., 2014; Hong and Banks, 2015). HIV-infected 
macrophages and microglia release viral proteins and cytokines eliciting an inflammatory 
response that disturbs neuronal network activity and causes progressive loss of cognitive 
function (Ellis et al., 2007). In response to excess excitatory drive produced by HIV-
associated neuroinflammation, neurons decrease the number of excitatory synapses 
(Bellizzi et al., 2006; Kim et al., 2008b; Green et al., 2018; Guha et al., 2018).  Loss of 
excitatory synapses correlates with cognitive decline in HAND (Ellis et al., 2007). Normal 
network activity requires balanced excitatory and inhibitory neurotransmission (Pozo and 
Goda, 2010). Changes in inhibitory signaling are also associated with excitotoxicity and 
neuroinflammation. 
Neurons exposed to the inflammatory cytokine interleukin-1β (IL-1β) increase 
surface expression of γ-aminobutyric acid type A receptors (GABAARs) (Serantes et al., 
2006), suggesting that inhibitory neurotransmission can be influenced by inflammatory 
pathways. Excessive upregulation of GABAergic signaling in response to inflammatory 
and excitotoxic stress impairs cognitive function. For example, in models of stroke, excess 
GABAergic tone impairs network recovery (Orfila et al., 2017) and in schizophrenia 
patients, increased synaptic α2 subunit-containing GABAA receptors are associated with 
cognitive dysfunction (Impagnatiello et al., 1998; Lewis et al., 2004; Guidotti et al., 2005).  
Upregulation of GABAergic synaptic markers also occurs following prolonged exposure to 
HIV neurotoxins, suggesting that excess inhibitory signaling may be involved in HAND as 
well (Fitting et al., 2013; Hargus and Thayer, 2013).  At present, how GABA-mediated 
inhibition is regulated during HIV-induced neuroinflammation is not known. 
HAND pathogenesis occurs primarily through an indirect mechanism mediated by 
the release of toxic agents, such as the HIV envelope protein gp120. HIV gp120 is shed 
by infected cells (Kaul et al., 2001), elicits neurotoxicity at picomolar concentrations 
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(Meucci and Miller, 1996; Kim et al., 2011; Zhou et al., 2017), and has been detected in 
the brains of patients with HAND (Jones et al., 2000). HIV gp120 evokes synaptic and 
behavioral deficits in vivo that mimic significant aspects of HAND (Toggas et al., 1994; 
Thaney et al., 2018). In this study, we used an in vitro model to study changes in inhibitory 
synapses during exposure to the neuroinflammatory stimulus HIV gp120. The envelope 
protein evoked the release of IL-1β from microglia. The resulting stimulation of IL-1 
receptors on neurons activates a Src and NMDA receptor pathway that increases the 
number of inhibitory synapses. This pathway overcame a basal suppression of inhibitory 
synapse number mediated by p38 MAPK. Recognizing that these two pathways regulate 
inhibitory synapse number, and that there is crosstalk between these pathways, provides 
insight into the neuronal response to inflammation and may guide the development of 
therapeutics targeting inhibitory signaling in HAND. 
 
II. Materials and Methods 
Materials 
Materials were obtained from the following sources: IL-1β (catalog number: 501-
RL-010) and IL-1 receptor antagonist (IL-1ra) (catalog number: 1545-RA-025) were from 
R&D Systems (Minneapolis, MN, USA); 3-(4-chlorophenyl) 1-(1,1-dimethylethyl)-1H-
pyrazolo[3,4-d]pyrimidin-4-amine (PP2) (catalog number: 1407), 1-Phenyl-1H-
pyrazolo[3,4-d]pyrimidin-4-amine (PP3) (catalog number: 2794), 3-Chloro-4-fluoro-N-[4-
[[2-(phenylcarbonyl)hydrazino]carbonyl]benzyl]benzenesulfonamide (TCN201) (catalog 
number: 4154), cycloheximide, 4-[5-(4-Fluorophenyl)-2-[4-(methylsulfonyl)phenyl]-1H-
imidazol-4-yl]pyridine (SB203580) (catalog number: 1202), trans-4-[4-(4-Fluorophenyl)-5-
(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl]cyclohexanol (SB239063) (catalog number: 
1962), 6-Cyano-7-nitroquinoxaline-2,3-dione disodium (CNQX) (catalog number: 1045), 
bicuculline methiodide, and tetrodotoxin (TTX) (catalog number: 1069) were from Tocris 
Bioscience (Bristol, UK); 4-Ethyl-2(p-methoxyphenyl)-5-(4ʹ-pyridyl)-IH-imidazole 
(SB202474) was from Millipore Sigma (catalog number: 559387; St. Louis, MO, USA). 
Dulbecco's modified Eagle's medium (DMEM) (catalog number: 31053), Hanks' balanced 
salt solution (catalog number: 14175), fetal bovine serum (catalog number: 26140), horse 
serum (catalog number: 16050) and penicillin/streptomycin (catalog number: 15140) were 
from ThermoFisher Scientific (Carlsbad, CA, USA). The expression vector for 
GPHN.FingR-eGFP, pCAG-GPHN.FingR-eGFP, was generated by Don Arnold’s 
laboratory and obtained from Addgene (catalog number: 46296; Cambridge, MA, USA). 
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The expression vector for synapsin driven tdTomato was generated by inserting tdTomato 
from pLVX-tdTomato-N1 (catalog number: 632563; Clontech-Takara Bio, Mountain View, 
CA, USA) into the pSyn backbone of pSyn-PSD95-GFP provided by Kirill Martemyanov 
(Scripps Research Institute, Jupiter, FL, USA). The plasmid for RapR-p38 expression 
(pCMV5-Flag-RapR-p38) was generated in Klaus Hahn’s laboratory and obtained from 
Addgene (catalog number: 25935). HIV-1 gp120IIIB was from the National Institutes of 
Health (NIH) AIDS Reagent Program, Division of AIDS, National Institute of Allergy and 
Infectious Diseases, NIH (catalog number:11784). 
 
Cell culture 
All animal care and experimental procedures were performed following the Guide 
for the Care and Use of Laboratory Animals published by the U.S. National Institutes of 
Health. Ethical approval was granted by the Institutional Animal Care and Use Committee 
of the University of Minnesota (protocol 1612-34372A). Primary hippocampal cultures 
were derived from fetal Sprague Dawley rats (RRID:MGI:5651135, Charles River, 
Wilmington, MA, USA) as described previously (Zhang and Thayer, 2018). Rats were 
euthanized by CO2 inhalation then hippocampi from embryonic day 17 fetuses were 
dissected and placed in Ca2+ and Mg2+ free Hanks’ balanced salt solution (HBSS). 
Hippocampi were dissociated by trituration with flame-narrowed Pasteur pipettes of 
decreasing aperture in DMEM supplemented with 10% fetal bovine serum and 
penicillin/streptomycin (100 U mL-1 and 100 mg mL-1, respectively). Cells were plated onto 
Matrigel-coated (150 µL, 0.2 mg mL-1, BD Biosciences, Billerica, MA, USA) glass-
bottomed Petri dishes. Cultures were kept in a humidified atmosphere of 10% CO2 and 
90% air (pH 7.4) at 37 OC. Culture media was exchanged on day 1 and 8 in vitro with 
DMEM supplemented with 10% horse serum and penicillin/streptomycin. All cultures were 
maintained for 12-16 days in vitro prior to use in experiments. These cultures contain 24 
± 4% neurons, 55 ± 4% astrocytes and 13 ± 6% microglia (Zhang and Thayer, 2018). 
 
Transfection 
Cultures were transfected using a previously described calcium phosphate 
procedure (Zhang and Thayer, 2018).  After 11- or 12-days in vitro, culture media was 
exchanged with DMEM containing 1 mM kynurenic acid, 10 mM MgCl2, and 5 mM HEPES.  
A DNA/calcium phosphate precipitate containing 0.5 µg of total plasmid DNA per well was 
allowed to form at room temperature for 1.5 h, then added dropwise to the cells.  After a 
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1 h incubation, cells were washed twice with DMEM supplemented with 10 mM MgCl2 and 
5 mM HEPES and conditioned media saved at the beginning of the procedure was 
returned to the cells. Experiments were started 2-3 days after transfection. 
 
Confocal imaging and image processing 
Confocal imaging and image processing were performed as previously described 
(Zhang and Thayer, 2018). Petri dishes containing transfected cells were placed in an 
incubator (LCI, Seoul, Korea; 37 °C and 10% CO2) on the stage of an inverted laser 
scanning confocal microscope (Nikon A1, Melville, NY, USA) and imaged with a 60 x (1.4 
numerical aperture) oil-immersion objective. Optical sections spanning 9 µm (1 µm per 
step) in the z-dimension were collected and combined into a maximum z-projection. GFP 
was excited at 488 nm and emission collected from 500 to 550 nm. TdTomato was excited 
at 561 nm and emission collected from 570 nm to 620 nm. After imaging, cells were 
returned to the cell culture incubator and the coordinates of the computer-controlled stage 
saved to allow repeated imaging of the same cell at later time points. 
An algorithm written in MetaMorph 7 (RRID:SCR_002368, San Jose, CA, USA) was 
used to count the GFP puncta in an unbiased manner (Waataja et al., 2008). A threshold 
0.25 times the standard deviation above the image mean was applied to the red image 
creating a 1-bit image. This binary image was used as a mask via a logical AND function 
with the green channel maximum z-projection. A top-hat filter (80 pixels) was applied to 
the masked green image. A threshold set 1.5 standard deviations above the mean 
intensity inside the mask was then applied to the contrast enhanced image. Punctate 
structures between 12 and 80 pixels (0.13-0.86 µm2) were counted as postsynaptic 
densities. Changes in the number of GPHN.FingR-GFP puncta from 2-3 microscopic fields 
from a single dish were averaged and considered an individual sample (n =1). 
 
Electrophysiology 
Electrodes were pulled using a horizontal micropipette puller (P-87; Sutter 
Instruments) from glass capillaries (Narishige). Pipette resistance was 3–5 MΩ. Miniature 
inhibitory postsynaptic currents (mIPSCs) were recorded with the following extracellular 
solution (in mM): 140 NaCl, 5 KCl, 9 CaCl, 6 MgCl, 5 glucose, and 10 HEPES, pH adjusted 
to 7.4 with NaOH. The intracellular recording solution was composed of (in mM): 140 KCl, 
0.2 EGTA, 10 HEPES, 10 glucose, 5 MgATP, and 0.3 NaGTP, pH adjusted to 7.2 with 
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KOH. Whole-cell voltages were amplified with an AxoPatch 200B (Molecular Devices), 
low-pass filtered at 2 kHz, and digitized at 10 kHz with a Digidata 1322A digitizer and 
pClamp software (Molecular Devices). Cells with series resistance over 25 MΩ were 
excluded from analysis. For mIPSCs recordings cells were voltage clamped at -70 mV in 
the presence of 3 µM CNQX, 50 µM APV, and 100 nM TTX. Data were analyzed with 
miniAnalysis software (Synaptosoft) using a threshold of 15 pA. 
 
Statistics 
All data are presented as mean ± SEM. Data distributions were determined using 
the D'Agostino-Pearson normality test and homogeneity of variances determined using 
Bartlett's test; all statistical tests were performed on normally distributed data of equal 
variance. Student’s t-test (unpaired two-tailed) was used for statistical analysis in two-
group comparison. For comparison among multiple groups, one-way or two-way ANOVAs 
were performed with Tukey’s post hoc test. Time course data were analyzed with a two-
way repeated measures ANOVA.  Statistical significance was defined as p<0.05. Sample 
sizes were not statistically predetermined but conform to similar studies. A test for outliers 
was not performed in this study. For imaging inhibitory synapses, the change in puncta 
from 2-3 fields from a single dish were averaged and considered as n=1. Imaging 
experiments included data from at least 8 dishes from 3-5 different cell culture platings. 
Gephyrin puncta were counted using an objective image processing algorithm that 
obviated the need to blind the experimenter. No other blinding methods were employed in 
this study.  All statistical analyses were performed using Prism, GraphPad 7 (La Jolla, CA 
92037 USA). 
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III. Results 
HIV gp120IIIB increases the number of inhibitory synapses 
The number of inhibitory synapses between hippocampal neurons in culture was 
determined by counting puncta produced by expression of a fluorescent antibody-like 
protein in live cells. Rat hippocampal cultures were transfected with plasmids that express 
a red fluorescent protein (tdTomato) to resolve cell morphology and a recombinant 
intrabody (GPHN.FingR-eGFP) that binds to gephyrin, a scaffolding protein located at the 
postsynaptic terminal of inhibitory synapses (Tyagarajan and Fritschy, 2014) (Figure 
3.1A). Previous studies have shown that GPHN.FingR-eGFP expressed in rat neurons 
labels synaptic structures as indicated by co-localization of intrabody enhanced green 
fluorescent protein (EGFP) puncta with endogenous gephyrin (Gross et al., 2013). To 
quantify the number of inhibitory synapses, an image processing algorithm was used to 
count fluorescent puncta meeting size and intensity criteria that were in contact with a 
binary mask created from the tdTomato image (Figure 3.1A). Functional analysis revealed 
that the number of labeled gephyrin puncta correlates with the frequency of mIPSCs 
(Figure 3.1B) indicating that fluorescent puncta identify functional synapses. To determine 
whether gp120 influences the number of inhibitory synapses, transfected neurons were 
imaged before (0 h) and 4 and 24 h after treatment with 600 pM gp120. Treatment with 
gp120 for 24 h increased the number of intrabody-labeled gephyrin puncta by 18 ± 5% 
compared to untreated control (Figure 3.1C, D). The number of inhibitory synapses was 
unchanged after 4 h exposure to gp120, indicating that the increase occurred in a time-
dependent manner.  To determine if gp120 affected neuronal survival, we calculated the 
percentage of neurons that retained tdTomato fluorescence at the 24 h time point for the 
experimental cohorts included in Figure 3.1D.  In the untreated control group, 84 ± 4 % of 
neurons survived; in gp120 treated group, 89 ± 9 % of the neurons survived, indicating 
that treatment with gp120 did not elicit significant neuronal death (Unpaired two-tailed t-
test; t(8)=0.48, p=0.65, n=5). This result is consistent with a previous cell survival study 
from our lab using a propidium iodide uptake assay that found 600 pM gp120 did not 
induce significant neuronal death until after exposure for 48 h (Kim et al., 2011). To 
determine if the effects of gp120 required intact tertiary structure and also to exclude a 
possible contribution from endotoxin contamination in the gp120 stock, transfected 
neurons were imaged before (0 h) and 24 h after treatment with 600 pM gp120 or heat-
inactivated gp120 (HI-gp120, 95 °C for 1 h). Treatment with HI-gp120 did not increase the 
number of inhibitory synapses (Figure 3.1E). 
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Figure 3.1 gp120 increases the number of inhibitory synapses. (A) Representative 
confocal images of a neuron expressing GPHN.FingR-eGFP and tdTomato were acquired 
and processed as described in Methods. Identified gephyrin puncta (yellow) were dilated 
and overlaid on the tdTomato maximum projection (Processed) for display purposes. 
Insets are enlarged images of the boxed regions. Scale bars represent 10 µm. (B) The 
number of gephyrin puncta correlates with the frequency of mIPSCs (r(4)=0.95, p=0.004, 
n=6; data from 2 independent cell preparations). (C) Representative processed confocal 
images and (D) plot showing time-dependent increase in the number of gephyrin labelled 
inhibitory synapses following treatment with gp120 (600 pM) (two-way repeated measures 
ANOVA; F(2, 26)= 6.61, p=0.005, n=14; data from 5 independent cell preparations). (E) 
Treatment with 600 pM gp120 for 24 h increased the number of gephyrin labelled inhibitory 
synapses.  Heat-inactivated gp120 (HI-gp120) did not affect the number of inhibitory 
synapses.  (One-way ANOVA; F(2,29)=9.43, p=0.0007, n=10 for control and HI-gp120 
group; n=12 for gp120 treated group; data from 3 independent cell preparations). Insets 
are enlarged images of the boxed regions. Scale bars represent 10 µm. Data are 
expressed as mean ± SEM. Two-way repeated measures ANOVA or one-way ANOVA 
was followed with Tukey’s post hoc test, **p<0.01, compared to control group (n=number 
of individual dishes in each group). 
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HIV gp120 activates CXCR4 to release IL-1β from microglia to upregulate inhibitory 
synapses 
The IIIB strain of the HIV-1 envelope protein gp120 binds to its co-receptor C-X-C 
chemokine receptor type 4 (CXCR4) and CD4 to initiate viral entry. The interaction of 
gp120 with CXCR4 activates microglia to release inflammatory cytokines that affect 
neurons (Viviani et al., 2006; Kim et al., 2011; Zhang and Thayer, 2018). To determine 
whether this receptor was involved in the gp120-induced increase in the number of 
intrabody-labeled gephyrin puncta, we co-treated neuronal cultures with the CXCR4 
antagonist AMD3100 (1 µM) and gp120. AMD3100 prevented the increase in gephyrin 
puncta evoked by 24 h treatment with gp120 (Figure 3.2A). CXCR4 is expressed in 
microglia, astrocytes, and neurons (Bonavia et al., 2003), which are all present in our 
primary hippocampal cultures. To test whether microglia were necessary for the effects of 
gp120, we eliminated microglia from the culture by treating with Leucine-Methyl-Ester 
(LME) (25 mM for 1 h followed by DMEM wash, or DMEM for 1 h followed by DMEM wash 
for control) 24 h prior to treating with gp120. LME treatment reduced the number of 
microglia by 95% compared to DMEM wash controls, as determined by 
immunocytochemistry with the Ox-42 antibody. Elimination of microglia prior to treatment 
with gp120 prevented the increase in intrabody-labeled gephyrin puncta compared to 
DMEM wash controls (Figure 3.2B). 
The interaction of gp120 with CXCR4 on microglia can evoke the release of 
inflammatory cytokines such as IL-1β. IL-1β increases the amplitude of evoked IPSCs 
(Hellstrom et al., 2005) and surface expression of functional GABAARs (Serantes et al., 
2006). Here we examined the role of IL-1β in the gp120-induced up-regulation of inhibitory 
synapses. Treatment with IL-1β (3 ng/mL) for 24 h significantly increased the number of 
intrabody-labeled gephyrin puncta by 24 ± 4 % compared to control (Figure 3.2C). Thus, 
IL-1β mimics the effects of gp120 on the number of inhibitory synapses. To determine 
whether the gp120-induced increase in inhibition is mediated by IL-1β, cultures were co-
treated with 1 µg/ml IL-1 receptor antagonist (IL-1ra) and gp120 (600 pM). IL-1ra 
prevented the gp120-induced increase in the number of intrabody labeled gephyrin puncta 
(Figure 3.2D). Collectively, these results indicate that gp120 activates CXCR4 on microglia 
to stimulate a neuroinflammatory pathway to release IL-1β that acts on its receptor to alter 
the number of inhibitory synapses. 
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Figure 3.2 gp120-evoked release of IL-1β from microglia upregulates the number 
of inhibitory synapses. (A) CXCR4 antagonist, AMD3100 (1 µM), inhibits gp120-
induced (600 pM) increases in the number of intrabody-labeled gephyrin puncta (24 h) 
relative to initial puncta count (0 h) (two-way ANOVA; F(1,42)=9.45, p=0.004, n=11 for 
control; n=12 for gp120 treated groups; data from 4 independent cell preparations). (B) 
Removal of microglia by 1 h treatment with 25 mM LME blocks gp120-induced increases 
in the number of inhibitory synapses (two-way ANOVA; F(1,53)=6.10, p=0.02; data from 5 
independent cell preparations) compared to DMEM wash (n=14). (C) IL-1β (3 ng/mL for 
24 h) alone increases the number of inhibitory synapses (Unpaired two-tailed t-test; 
t(16)=4.8, p=0.0002, n=9; data from 3 independent cell preparations). (D) IL-1ra (1 µg/mL) 
blocks the gp120-induced increase in the number of inhibitory synapses (two-way 
ANOVA; F(1,36)=8.03, p=0.008, n=10; data from 4 independent cell preparations). Data 
are expressed as mean ± SEM. Two-way ANOVAs were followed by Tukey’s post hoc 
test, *p<0.05, **p<0.01, ***p<.001 compared to untreated control. # p<0.05, ##p<0.01, 
compared to gp120 alone (untreated) (n=number of individual dishes in each group). 
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Basal p38 MAPK activity suppresses the number of inhibitory synapses 
IL-1 receptor activation was previously shown to couple to the p38 mitogen-
activated protein kinase (p38 MAPK) pathway to inhibit long-term potentiation (Kelly et al., 
2003) and upregulation of this pathway is also reported to induce synaptic changes 
associated with neurodegenerative disease (Sama and Norris, 2013). Therefore, we 
tested whether inhibition of p38 affected the number of inhibitory synapses. Treatment 
with SB203,580 (10 µM), a selective p38 MAPK inhibitor, alone induced an increase in 
gephyrin puncta (Figure 3.3A, B). This increase was not observed with the inactive analog 
SB202474 (10 μM) (Figure 3.3C), and was also observed with a second p38 inhibitor, 
SB239063 (10 μM) (Figure 3.3D). These data suggest that p38 tonically suppresses 
GABAergic neurotransmission by decreasing the number of inhibitory synapses. To 
further explore the role of p38, we employed a genetic approach. RapR-p38 is a 
genetically modified p38 kinase that acts as a dominant negative when expressed in the 
presence of wild type p38. RapR-p38 is activated by rapamycin, enabling regulation of 
p38 activity independent of its upstream physiological signaling pathway (Karginov et al., 
2010). In cells expressing RapR-p38, tdTomato and GPHN.FingR-eGFP, rapamycin 
treatment reduced the number of inhibitory synapses by 19 ± 3% compared to those not 
treated with rapamycin (Figure 3.3E). Thus, activation of p38 is sufficient to suppress the 
formation of new inhibitory synapses under basal conditions. 
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Figure 3.3 p38 MAPK mediates basal suppression of the number of inhibitory 
synapses. (A) Representative processed confocal images and (B) bar graph showing 
the p38 antagonist SB203,580 (10 µM) alone increases the number of intrabody-labeled 
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gephyrin puncta (24 h) relative to untreated (Unpaired two-tailed t-test; t(16)=2.21, p=0.04, 
n=9; data from 3 independent cell preparations). (C) SB202474 (10 µM), an inactive 
analog of SB203580, does not affect the gp120-induced (600 pM) increase in the number 
of intrabody-labeled gephyrin puncta (24 h)(Unpaired two-tailed t-test; t(18)=0.004, p= 1, 
n=10; data from 3 independent cell preparations). (D) The number of intrabody-labeled 
gephyrin puncta is increased by 24 h treatment with SB239063 (10 µM), a p38 MAPK 
inhibitor (Unpaired two-tailed t-test; t(14)=4.95, p=0.0002, n=8; data from 3 independent 
cell preparations). (E) Treatment with rapamycin (200 nM) decreases the number of 
inhibitory synapses in cells expressing RapRp38 (Unpaired two-tailed t-test, t(14)=3.71, 
p=0.002; data from 3 independent cell preparations) but not untreated cells (Unpaired 
two-tailed t-test, t(14)=0.43, p=0.7; data from 3 independent cell preparations) (n=8). Data 
are expressed as mean ± SEM, *p<0.05, **p<0.01, ***p<.001 compared to control 
(n=number of individual dishes in each group). 
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HIV gp120 activates Src and GluN2A-containing NMDARs to increase the number 
of inhibitory synapses 
IL-1β stimulates phosphorylation of NMDARs by Src family kinases (SFKs) (Viviani 
et al., 2003; Viviani et al., 2006). Over activation of NMDARs leads to an increase in the 
number of inhibitory synapses following exposure to the HIV protein Tat (Hargus and 
Thayer, 2013). Thus, to determine the downstream mechanism for the gp120-induced 
increase in inhibitory synapses, we used the selective SFK inhibitor, PP2, to determine 
whether the gp120-induced increase in inhibitory postsynaptic sites is mediated by SFKs. 
PP2 (10 μM), but not the inactive analog PP3 (10 μM), prevented the gp120-induced 
increase in intrabody-labeled gephyrin puncta (24 h) (Figure 3.4A, B, C). The SFKs Src 
and Fyn have been shown to regulate inhibitory synaptic transmission (Ohnishi et al., 
2011). To determine the specific SFK responsible for the gp120-induced increase in 
inhibitory synapses and to compliment the pharmacological approach with a genetic 
method, cultures were co-transfected with expression plasmids for tdTomato and gephyrin 
intrabody with or without plasmids that encode dominant-negative Src (DN-Src) or 
dominant-negative Fyn (DN-Fyn) (Mariotti et al., 2001). Gp120 treatment increased the 
number of intrabody labeled gephyrin puncta in both untreated neurons and neurons 
expressing DN-Fyn (Fig. 4D). However, in neurons expressing DN-Src, gp120 failed to 
induce a significant increase in inhibitory synapses (Figure 3.4D). These data suggest that 
Src mediates the gp120-induced increase in the number of inhibitory synapses. 
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Figure 3.4 HIV gp120-induced upregulation of the number of inhibitory synapses 
requires Src. (A) Representative confocal images and (B) bar graph showing that the 
Src family kinase inhibitor PP2 (10 µM) reduced gp120-induced increase in the number 
of intrabody-labeled gephyrin puncta (two-way ANOVA; F(1,45)=5.10, p=0.03, n=13 for 
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untreated control; n=12 for other groups; data from 5 independent cell preparations). (C) 
PP3 (10 µM), an inactive analog of PP2, does not affect the gp120-induced (600 pM) 
increase in the number of inhibitory synapses (two-way ANOVA; F(1, 43)=0.012, p=0.9, 
n=13 for untreated control; n=12 for untreated gp120 group; n=12 for PP3 control group; 
n=10 for PP3 gp120 group; data from 5 independent cell preparations). (D) gp120 
induces an increase in the number of intrabody-labeled gephyrin puncta in untreated 
cultures (t(25)=3.47, p=0.002, n=13 for untreated control; n=14 for untreated gp120 group) 
and cultures expressing dominant-negative Fyn (t(23)=2.58, p=0.02, n=13 for Fyn control 
group; n=12 for Fyn gp120 treated group), but in cultures expressing dominant-negative 
Src the gp120-induced response was blocked (Unpaired two-tailed t-test; t(24)=1.04, 
p=0.3, n=13; data from 6 independent cell preparations). Two-way ANOVAs were 
followed by Tukey’s post hoc test, *p<0.05, **p<0.01 compared to control. # p<0.05 
compared to gp120 alone (untreated) (n=number of individual dishes in each group). 
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Src phosphorylates NMDARs increasing their activity (Kohr and Seeburg, 1996). 
Thus, we tested whether NMDA receptors mediate the gp120-induced increase in 
inhibition. In previous work, we found that synaptic changes induced by HIV proteins were 
mediated by GluN2A-containing NMDARs (Hargus and Thayer, 2013; Shin and Thayer, 
2013). TCN201 (10 µM), an inhibitor of GluN2A-containing NMDARs, prevented the 
gp120-induced increase in intrabody-labeled gephyrin puncta (24 h) (Figure 3.5A). 
Increases in the number of inhibitory synapses could result from potentiated GABAAR 
function, insertion of intracellular GABAARs, or gene expression and production of new 
receptors (Kneussel and Hausrat, 2016). To determine whether the gp120-induced 
increase in inhibition requires gene expression, we pre-treated the culture with the protein 
synthesis inhibitor, cycloheximide (CHX) (10 µM). CHX prevented the gp120-induced 
increase in intrabody labeled puncta (Figure 3.5B).  These data indicate that translation 
following activation of Src and GluN2A-containing NMDARs is required for the gp120-
induced increases in intrabody labeled gephyrin puncta. 
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Figure 3.5 Upregulation of the number of inhibitory synapses requires GluN2A-
containing NMDARs and protein synthesis. (A) TCN201 (10 µM), an antagonist for 
GluN2A-containing NMDARs blocks the gp120-induced increase in the number of 
intrabody-labeled gephyrin puncta (two-way ANOVA; F(1,42)=10.93, p=0.002, n=12 for 
untreated groups; n=11 for TCN201 treated groups; data from 4 independent cell 
preparations). (B) The protein synthesis inhibitor cycloheximide (CHX) (10 µM) blocks the 
gp120-induced increase in the number of inhibitory synapses (two-way ANOVA, 
F(1,39)=9.29, p=0.004, n=11 for untreated control; n=10 for untreated gp120 group; n=11 
for CHX treated groups; data from 4 independent cell preparations). Data are expressed 
as mean ± SEM. Two-way ANOVAs were followed by Tukey’s post hoc test, *p<0.05, 
**p<0.01 compared to control. ##p<0.01, ###p<0.001 compared to gp120 alone (untreated) 
(n=number of individual dishes in each group). 
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IV. Discussion 
Elevated inhibitory signaling is associated with many neurodegenerative 
conditions (Fernandez et al., 2007; Hines et al., 2012; Wu et al., 2014). In this study, we 
examined how inhibitory synapses are affected in an in vitro model of HIV-associated 
neuroinflammation. Using an imaging-based approach to quantify GABAergic synapses 
in living neural networks, we found that gp120, a potent neurotoxin that in vivo mimics 
significant aspects of HAND (Toggas et al., 1994), increased the number of inhibitory 
synapses between hippocampal neurons. The effects of gp120 were mediated by the 
release of the inflammatory cytokine IL-1β from microglia, consistent with previous studies 
(Louboutin et al., 2010; Kim et al., 2011), and suggesting that the synaptic changes we 
observed are broadly relevant to neuroinflammatory conditions. Stimulation of IL-1 
receptors activated a Src-NMDAR pathway to increase GABAergic synapses. This 
pathway reversed a tonic p38 MAPK-mediated suppression of inhibitory synapse number, 
suggesting that during neurotoxic challenge this upregulation overcomes a basal 
regulatory process. This novel dual mechanism of control provides insights into the 
regulation of inhibitory synapses at rest and during neuroinflammation that may identify 
approaches to improve cognitive function in HAND. 
This study is based on a synaptic imaging approach. The method uses a 
recombinant antibody-like protein (intrabody) linked to EGFP, which binds to the post-
synaptic scaffolding protein gephyrin and forms fluorescent clusters around inhibitory 
synapses. Intrabodies do not induce the formation of new inhibitory synapses as may 
occur with EGFP gephyrin fusion proteins previously used (Hargus and Thayer, 2013).  
Electrophysiological analysis demonstrated that the labeled puncta number correlates 
with mIPSC frequency, confirming that intrabody labelled sites represent functional 
inhibitory synapses. The principal advantage of the live-cell synaptic imaging approach is 
synapse counts from the same region of interest can be imaged before and after treatment 
enabling synapse count, which varies considerably between cells, to be normalized to its 
pre-treatment value. While we have not performed in vivo validation for the specific 
synaptic changes described in this report, the loss of excitatory synapses induced by HIV 
proteins using this same cell culture model was replicated in vivo in experiments in which 
pharmacological rescue of synapses also reversed cognitive impairment (Raybuck et al., 
2017). Thus, synaptic changes observed in this mixed glial and neuronal culture have 
effectively predicted similar outcomes in vivo. 
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HIV gp120 has been detected in the brains of HIV-infected patients with dementia 
using immunohistochemistry (Jones et al., 2000).  We are not aware of a quantitative 
measure of gp120 levels in brain or cerebrospinal fluid (CSF) of HIV patients.  However, 
high levels of anti-gp120 antibody have been detected in the CSF compared to serum in 
HIV patients with cognitive deficits, suggesting accumulation of gp120 in the CSF (Trujillo 
et al., 1996).  The levels of gp120 in the plasma, serum, and other tissues from HIV 
patients range from 0.3 to 92 ng/ml depending on the tissue (Oh et al., 1992; Santosuosso 
et al., 2009; Rychert et al., 2010). Thus, the 600 pM (72 ng/ml) concentration of gp120 
used in this study is comparable to that found in the tissues of HIV infected individuals. 
HIV gp120 activated CXCR4 to evoke the release of IL-1β from microglia. This 
observation is consistent with the tropism of the IIIB strain of gp120 which binds to CXCR4 
(Moore et al., 1997; Islam et al., 2013).  Recombinant gp120IIIB has previously been 
demonstrated to induce release of inflammatory cytokines including IL-1β from human 
monocytes (Clouse et al., 1991). HIVIIIB is a widely studied laboratory strain that was not 
isolated from the CNS of HAND patients. However, CCR5 tropic gp120 has been found in 
HIV-infected brain and induces an inflammatory response similar to the gp120IIIB-evoked 
response described here, including release of IL-1β in both rodent brain and cultured 
human microglia (Ashraf et al., 2014; Walsh et al., 2014). Thus, the IL-1β dependent 
increase of inhibitory synapses evoked by the CXCR4 preferring gp120 used here would 
also be predicted to result from exposure to CCR5 preferring strains. Furthermore, 
neuronal injury resulting from expression of gp120IIIB is prevented in CCR5 knockout mice, 
suggesting an indirect pathologic role for CCR5 in CXCR4-initiated neuroinflammation 
(Maung et al., 2014). 
HIV neurotoxicity is indirect resulting from the release of viral proteins and 
inflammatory cytokines from infected microglia and macrophages (Ellis et al., 2007; Saylor 
et al., 2016). For productive infection, HIV gp120 interacts with a chemokine receptor 
(CXCR4 or CCR5) and CD4 to gain cell entry (Deng et al., 1996; Berger et al., 1999).  
Rodent models like the cell culture studied here, cannot be infected by HIV because they 
lack CD4 expression. However, gp120 can bind to and interact with chemokine receptors 
in the absence of CD4 (Hesselgesser et al., 1997; Kaul and Lipton, 1999).  The gp120IIIB 
used in this study binds to rodent CXCR4 and elicits the release of inflammatory cytokines 
(Clouse et al., 1991; Brelot et al., 1997; Bagetta et al., 1999; Bezzi et al., 2001).  Thus, 
results of this study are particularly relevant to gp120 shed from infected cells that then 
acts on additional non-infected cells. We have previously shown that treatment of the 
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same neuron-glia co-cultures used here with 600 pM gp120 increased expression of IL-
1β mRNA and release of IL-1β protein (Kim et al., 2011; Zhang and Thayer, 2018).  The 
concentration of IL-1β released into the cell culture media was 70 pg/mL which likely 
underestimates the local concentration in the culture monolayer and is lower than the 
concentration employed in this study to increase the number of inhibitory synapses.  
Treating the culture with threonine-lysine-proline, which blocks activation of microglia, 
inhibits gp120 evoked IL-1β release, suggesting that microglia are the primary source for 
IL-1β (Kim et al. 2011).  The gp120-evoked release of IL-1β replicates one of the 
neuroinflammatory mechanisms thought to mediate HAND and is consistent with studies 
from other laboratories showing that the highly potent effects that result from prolonged 
exposure to low concentrations (picomolar) of the envelope protein are indirect (Meucci 
and Miller, 1996; Viviani et al., 2006; Medders et al., 2010; Kim et al., 2011; Yang et al., 
2013). Upregulation of inhibitory synapses was blocked selectively by expression of 
dominant negative Src in neurons, suggesting that key steps in the downstream regulatory 
pathways are located within neurons. Neurons express IL-1Rs (Vezzani et al., 2011) but 
astrocytes also exhibit IL-1 receptor signaling (Ravizza and Vezzani, 2006) and could 
contribute to the effects described here. gp120-induced potentiation of NMDA receptor 
function and subsequent loss of excitatory synapses are also mediated by an IL-1β 
induced pathway (Zhang and Thayer, 2018), consistent with the key role of IL-1β in HIV 
gp120-induced neuronal injury. IL-1β mRNA and protein expression levels are increased 
significantly in the brain tissues of HIV positive patients (Persidsky and Gendelman, 1997; 
Xing et al., 2009; Walsh et al., 2014). In HIV-1 encephalitis patients, the expression of IL-
1β is signicantly higher compared to HIV seropositive or seronegative patients without 
HIV-1 encephalitis (Zhao et al., 2001). A slightly modified form of recombinant human IL-
1ra is currently being tested in a clinical trial for HAND (ClinicalTrials.gov Identifier: 
NCT02527460). The signaling pathway activated by gp120 and described here might 
reveal additional targets relevant to HAND pharmacotherapy. 
The gp120-evoked increase in the number of inhibitory synapses appears to be 
mediated by a homeostatic plasticity mechanism to counteract excessive excitation (Pozo 
and Goda, 2010; Green et al., 2018). We did not detect significant cell death during a 24 
h exposure to gp120 although, others have described a 23-55 % loss of neurons during a 
24-72 exposure to gp120 concentrations ranging from 200 pM to 100 nM (Medders et al., 
2010; Avdoshina et al., 2016; Liu et al., 2016). Our results suggest that there is an early 
adaptive, possibly protective, response that is initiated by the same potentiation of 
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NMDARs that triggers the cell death process. HIV gp120 potentiated NMDAR function via 
activation of the tyrosine kinase Src, a process known to sensitize the NMDAR to 
activation by glutamate (Viviani et al., 2006; Krogh et al., 2014; Green and Thayer, 2016; 
Zhang and Thayer, 2018). In hypothalamic neurons, IL-1 receptors couple to Src via 
MyD88-dependent production of ceramide (Davis et al., 2006) and in hippocampal 
neurons this pathway impairs spine structural remodeling (Tong et al., 2018).  IL-1β is pro-
convulsive and is thought to mediate some of the seizure promoting effects of 
inflammation (Rijkers et al., 2009). We have shown previously that following exposure to 
agents that potentiate NMDARs via Src activation, the synaptic network undergoes a 
series of adaptive changes over the next 18-24 h (Kim et al., 2008a; Kim et al., 2011; 
Green and Thayer, 2016; Zhang and Thayer, 2018). These adaptive mechanisms, 
including loss of excitatory synapses, appear to be part of a homeostatic plasticity 
mechanism that is not part of the neuronal death process (Shin et al., 2012; Raybuck et 
al., 2017; Green et al., 2018). We posit that the gp120-induced increase in inhibitory 
synapses is part of a coping mechanism that occurs during 24 h treatment with agents 
that potentiate NMDARs. Activation of GluN2A-containing NMDARs appears to regulate 
synaptic plasticity and be neuroprotective (Liu et al., 2007; Baez et al., 2018), whereas 
activation of GluN2B-containing NMDARs is associated with neuronal death pathways 
(Taghibiglou et al., 2009; Tu et al., 2010). The increase in inhibitory synapses was 
dependent on activation of GluN2A-containing NMDARs and protein synthesis, consistent 
with previous reports showing that activation of synaptic NMDARs triggers expression of 
pro-survival genes (Bading, 2017) and the idea that increased synaptic inhibition 
attenuates excitotoxicity. Thus, synaptic changes may be a mechanism to cope with over 
activation of NMDARs (Green et al., 2018). This study supports the idea that activation of 
potentiated GluN2A-containing NMDARs increases inhibitory synapse number as an 
adaptive mechanism to counteract excess excitation and promote neuronal survival. 
Gp120-induced neuroinflammation and subsequent activation of IL-1Rs increases 
the formation of inhibitory synapses, an adaptive process that might improve neuronal 
survival at the cost of impaired function. Increased inhibitory tone suppresses long-term 
potentiation (LTP) in the hippocampus (Arima-Yoshida et al., 2011; Schreurs et al., 2017). 
Enhanced GABAergic inhibitory signaling is associated with cognitive deficits in many 
neurodegenerative conditions. For example, excess GABA release from reactive 
astrocytes impairs memory in mouse models of Alzheimer’s disease (Jo et al., 2014) and 
increased synaptic α2-containing GABA receptors are associated with memory 
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dysfunction in schizophrenia (Lewis et al., 2004). Excessive inhibition of GABA 
transporters, a target of some antiepileptic drugs, produces cognitive deficits (Cavanna et 
al., 2010). Reversing the synaptic adaptations that occur under neuroinflammatory and 
excitotoxic conditions by recovering lost excitatory synapses and reducing upregulated 
inhibitory synapses may provide a novel strategy to improve cognitive function (Ryan et 
al., 2015; Calvo-Flores Guzman et al., 2018). However, if this form of synaptic scaling is 
a coping mechanism to improve neuronal survival, then it will be important to consider the 
potential adverse consequences of attenuating this protective mechanism when designing 
pharmacotherapies. 
Inhibition of p38 MAPK in naïve cultures increased the number of inhibitory 
synapses and activating a mutant form of p38 expressed in hippocampal neurons 
decreased the number of inhibitory synapses. This is consistent with previous work in rat 
and mouse hippocampal neurons showing that p38 activated phosphatidylinositol 3-
kinase, protein phosphatase 1, and dynamin GTPase to reduce trafficking of GABAARs to 
the cell surface (Pribiag and Stellwagen, 2013). These results indicate that there is basal 
activation of a p38 MAPK pathway in hippocampal neurons that constrains the number of 
inhibitory synapses. Medders et al (Medders et al., 2010) conducted an extensive analysis 
of p38 MAPK activation in a similar mixed neuron-glia co-culture. Consistent with our 
results they found p38 activated in neurons under basal conditions. They also found that 
gp120 activated p38 in microglia, possibly as a step in the secretory process. We did not 
address the role of p38 in microglia although, such a role is not inconsistent with our finding 
that microglial activation is upstream of the neuronal response. Activation of IL-1Rs 
stimulates p38 MAPK in hippocampal neurons (Tong et al., 2012). Thus, both p38 MAPK 
and Src-NMDAR pathways are upregulated and coordinately regulate the number of 
inhibitory synapses in the presence of gp120. The Src-NMDAR pathway is the dominant 
signal at the synapse in this condition. It appears that normal homeostatic balance 
between the two pathways is disrupted under neuroinflammatory conditions. 
This report shows for the first time that gp120 increases the number of inhibitory 
synapses through a neuroinflammatory mechanism initiated by IL-1β. The number of 
inhibitory synapses is coordinately regulated by both p38 MAPK and Src-NMDAR 
pathways with the Src-NMDAR pathway dominating under inflammatory conditions. 
Identifying the mechanisms that control the number of inhibitory synapses provides a 
better understanding of the pathogenesis of HAND and may guide the development of 
therapeutics targeting inhibitory signaling during neuroinflammation. 
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I. Introduction 
Synaptic transmission is important for fast information transfer, maintenance of 
homeostatic network activity, and the development of new synaptic connections (Abbott 
and Regehr, 2004; Fong et al., 2015; Kavalali, 2015). Evoked neurotransmitter release is 
the major form of synaptic transmission and occurs when presynaptic action potentials 
(APs) depolarize the nerve terminal activating voltage-gated Ca2+ channels to trigger Ca2+-
dependent synchronized-release of neurotransmitter. Spontaneous neurotransmission is 
independent of presynaptic APs and occurs in an asynchronous manner when a single 
synaptic vesicle releases its contents from the nerve terminal (Schneggenburger and 
Rosenmund, 2015). Emerging evidence suggests that spontaneous neurotransmission 
plays an important role in synaptogenesis (Huntwork and Littleton, 2007; Choi et al., 2014; 
Ramirez et al., 2017). However, the specific mechanism regulating the spontaneous 
release of neurotransmitter and how it relates to synapse formation is still not clearly 
understood. 
NMDA receptors (NMDARs) regulate both presynaptic glutamate release and 
postsynaptic Ca2+ influx during spontaneous neurotransmission (Reese and Kavalali, 
2016; Abrahamsson et al., 2017). Presynaptic GluN2B-containing NMDARs regulate 
spontaneous glutamate release in a manner insensitive to Ca2+ or Mg2+. Distinct 
populations of post-synaptic NMDARs are activated by evoked versus spontaneous 
glutamate release (Atasoy et al., 2008; Reese and Kavalali, 2016), suggesting the two 
release processes play distinct roles in neuronal networks. Recent work has shown that 
the frequency of spontaneous glutamate release regulates postsynaptic strength 
(Crawford et al., 2017). Antagonists for NMDARs stimulate synaptogenesis under certain 
conditions. For example, blocking GluN2B-containing NMDARs induces recovery in the 
number of glutamatergic synapses following synapse loss caused by excitotoxic proteins 
(Shin et al., 2012; Raybuck et al., 2017). The NMDAR antagonist ketamine also induces 
rapid synaptogenesis in animal models of depression (Ohgi et al., 2015). It is not clear 
whether the synaptogenic actions of antagonists for GluN2B-containing NMDARs result 
from inhibition of spontaneous neurotransmitter release. 
In this paper, we address the question of whether activation of presynaptic 
GluN2B-containing NMDARs regulate spontaneous glutamate release and if so, whether 
their blockade triggers new synapse formation. A genetically encoded ratiometric calcium 
indicator, GCaMP-6s-R, enabled us to examine both the frequency and amplitude of 
spontaneous spine calcium transients (SSCTs). Treatment with an antagonist selective 
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for GluN2B-NMDARs, Ro 25-6981, decreased the frequency but not amplitude of SSCTs, 
indicating presynaptic regulation of spontaneous neurotransmitter release. Treatment with 
Ro 25-6981 in the presence of TTX increased in the number of synapses, indicating that 
SSCTs regulated by presynaptic GluN2B-NMDARs control synapse formation. 
 
II. Materials and Methods 
Materials 
Materials were obtained from the following sources: 
(4R,6S,8S,10Z,12R,14R,16E,18R,19R,20S,21S)-11,19,21-Trihydroxy-4,6,8,12,14,18,20-
heptamethyl-22-[(2S,2'R,5S,5'S)-octahydro-5'-[(1R)-1-hydroxyethyl]-2,5'-dimethyl[2,2'-
bifuran]-5-yl]-9-oxo-10,16-docosadienoic acid (ionomycin free acid) (catalog number: 
2092); Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) (catalog number: 
0453); (6aR,11aS,11bR)-rel-10-Acetyl-2,6,6a,7,11a,11b-hexahydro-7,7-dimethyl-9H-
pyrrolo[1',2':2,3]isoindolo[4,5,6-cd]indol-9-one (cyclopiazonic acid) (catalog number: 
1235); (αR,βS)-α-(4-Hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidinepropanol 
maleate (Ro 25-6981 maleate) (catalog number: 1594); D‐(‐)‐2‐Amino‐5‐
phosphonopentanoic acid (APV) (catalog number: 0106); tetrodotoxin (TTX) (catalog 
number: 1069) were from Tocris Bioscience (Bristol, UK). Dulbecco's modified Eagle's 
medium (DMEM) (catalog number: 31053), Hanks’ balanced salt solution (catalog 
number: 14175), fetal bovine serum (catalog number: 26140), horse serum (catalog 
number: 16050), and penicillin/streptomycin (catalog number: 15140) came from 
ThermoFisher Scientific (Carlsbad, CA, USA). The expression plasmid for pCAG-
PSD95.FingR‐eGFP was generated by Don Arnold's laboratory and obtained from 
Addgene (catalog number: 46296; Cambridge, MA, USA). The expression plasmid pSyn-
tdTomato was generated as previously described (Zhang and Thayer, 2018). The 
expression plasmid pCaMKII-GCaMP-6s-R was generated by inserting GCaMP-6s-R 
from pCAG-GCaMP-6s-R kindly provided by Dr Jung-Hwa Cho (University of Southern 
California, Los Angeles, CA, USA) into the CaMKII backbone of pAAV-CaMKIIa-
hChR2(H134R)-EYFP, a gift from Dr. Karl Deisseroth (Addgene, catalog number: 26969). 
 
Primary Hippocampal Culture 
All animal care and experimental procedures were carried out according to the 
Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes 
of Health. Ethical approval was granted by the Institutional Animal Care and Use 
76 
 
Committee of the University of Minnesota (protocol 1612‐34372A). Primary hippocampal 
cultures were prepared from fetal Sprague–Dawley rats (RRID:MGI:5651135, Charles 
River, Wilmington, MA, USA) as previously described (Zhang and Thayer, 2018). All 
cultures were maintained for 11-14 DIV prior to use in experiments. These cultures contain 
24 ± 4% neurons, 55 ± 4% astrocytes, and 13 ± 6% microglia as previously described 
(Zhang and Thayer, 2018). 
 
Transfection 
Cultures were transfected using a previously described calcium phosphate 
procedure (Zhang and Thayer, 2018). Transfection was performed on DIV 11 or 12. 
Experiments were started 2–4 days post transfection. 
 
Live Cell Synaptic Imaging and Image Processing 
Live cell imaging of synapses was performed as described previously (Zhang and 
Thayer, 2018). An algorithm written in MetaMorph 7 (RRID:SCR_002368, San Jose, CA, 
USA) was used to count the number of GFP puncta in an unbiased manner (Waataja et 
al., 2008; Zhang et al., 2019). 
 
Ca2+ Imaging 
Ca2+ imaging was performed on cells 14-15 DIV and 2-4 days after transfection 
with pCamKII-GCaMP-6s-R. This tandem construct encodes the Ca2+-sensitive green-
fluorescent reporter GCaMP-6s and the calcium-insensitive red fluorescent-protein 
mCherry linked by a rigid α-helix (Cho et al., 2017). Thus, the ratio of detected green and 
red fluorescence directly relates to [Ca2+]i. Cover-glasses containing transfected cells were 
transferred to a recording chamber, placed on the stage of an inverted microscope 
(Olympus IX71, Melville, NY, USA), and imaged with a 60x oil immersion objective (1.4 
numerical aperture). Image series were collected at 10 Hz using a Photometrics Cascade 
512B EMCCD camera (Roper Scientific, Tucson, AZ, USA) controlled with MetaMorph 
software (San Jose, CA, USA). 10 frames were collected on the red channel before and 
after each 2 min green channel image series. Excitation was provided by two LEDs 
(Thorlabs, Newton, NJ, USA) combined with a 505 nm dichroic mirror and directed through 
the epifluorescence port with a collimating lens (Thorlabs, Newton, NJ, USA). The green 
channel was excited at 490 nm, reflected off a 524 nm dichroic, and emission collected at 
507 nm (40 nm band pass). The red channel was excited at 565 nm, reflected off a 640 
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nm dichroic, and emission collected at 610 nm (60 nm band pass) (Chroma, Vermont, 
U.S.A). All recordings were conducted at room temperature (21 °C) with the same LED 
power settings. During experimental recordings, cells were superfused with 1 μM TTX 
supplemented-Mg2+ free artificial cerebrospinal fluid (ACSF) at a rate of 1-2 ml/min for 2 
min followed by 1 μM TTX supplemented-Mg2+ free ACSF containing drugs or 
supplemented with Mg2+ for 2 min. After background subtraction, the red and green image 
intensities were converted to green/red ratios and further converted to intracellular Ca2+ 
concentration ([Ca2+]i). 
To detect SSCTs, green/red ratios were calculated for regions of interests (ROI) 
encompassing spontaneous activity during the recording. An SSCT was defined by an 
increase in the green/red ratio greater than two standard deviations above the average 
ratio from the previous 2 s and the slope calculated over both previous and current 200 
ms windows were greater than 0.15 /s. These criteria allow consideration of baseline 
changes resulting from bleaching or field drift. All detected peaks were counted to 
calculate frequency (event/min) and the amplitude further converted to Ca2+ concentration. 
 
Calibration of GCaMP-6s-R 
Calibration of GCaMP-6s-R expressed in rat hippocampal neurons was performed 
48 h after transfection (Fig. 1A). Neurons were sequentially superfused with normal 
artificial cerebrospinal fluid (ACSF), Ca2+-free ACSF + 1 mM EGTA, Ca2+-free ACSF + 1 
mM EGTA supplemented with ionomycin cocktail, 5 mM Ca2+ ACSF, and 5 mM Ca2+ ACSF 
supplemented with ionomycin cocktail. The ionomycin cocktail includes ionomycin (Ca2+ 
ionophore, 5 µM), FCCP (uncoupler of mitochondrial oxidative phosphorylation that 
eliminates the driving force for mitochondria Ca2+ uptake, 1 µM) (Baron et al., 2003), and 
cyclopiazonic acid (SERCA type Ca2+-ATPase inhibitor that blocks Ca2+ uptake to 
sarcoplasmic and endoplasmic reticulum Ca2+ stores, 10 µM) (Ghosh et al., 2011; Cho et 
al., 2017). After background subtraction, the green (GCaMP-6s) and red (mCherry) image 
pairs were converted to [Ca2+]i using the formula [Ca2+]i = Kdβ(R − Rmin)/(Rmax − R) 
(Grynkiewicz et al., 1985). The dissociation constant (Kd) for GCaMP-6s-R was 258 nM 
(Cho et al., 2017). β is the ratio of fluorescence intensity acquired with mCherry excitation 
and emission wavelengths measured in Ca2+-free ACSF supplemented with ionomycin 
cocktail to that measured in 5 mM Ca2+ ACSF supplemented with ionomycin cocktail. R is 
green/red fluorescence intensity ratio. Rmin, Rmax, and β were determined in a series of 
calibration recordings like that shown in Figure 1A. Values for Rmin, Rmax, and β were 0.064 
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± 0.004, 0.72  ± 0.03 and 0.98 ± 0.11, respectively. These calibration constants were 
applied to all experimental recordings. 
 
Statistics 
The distributions of data were determined using D'Agostino‐Pearson normality test 
and homogeneity of variances determined using Bartlett's test; all statistical tests were 
performed on data of normal distribution with equal variance. For statistical analysis in 
two-group comparisons, unpaired two-tailed Student’s t-test was used. For comparison 
among multiple groups, one-way ANOVA were performed with Tukey’s post hoc test. 
Statistical significance was defined as p < 0.05. Sample sizes were not statistically 
predetermined but conform to similar studies. A test for outliers was performed in Microsoft 
Excel 2010 (Redmond, WA, USA). Data points that are more than 1.5 times interquartile 
ranges below the first quartile or above the third quartile were considered as outliers and 
removed.  For imaging of SSCTs, spike amplitude or frequency from all the active spines 
in the field were averaged and considered as n = 1. For imaging excitatory synapses, the 
change in PSD95.FingR-eGFP puncta from two to three fields from one dish were 
averaged as n = 1. Each experiment included data from at least 7 dishes from three to six 
different platings. PSD95 puncta were counted using an automated image processing 
algorithm that obviated the need to blind experimenters. No other blinding methods were 
applied. All data are presented as mean ± SEM. Statistical analyses except for the test for 
outliers were performed using Prism, GraphPad 7 (La Jolla, CA 92037 USA). 
 
III. Results 
Ratiometric GCaMP-6s-R detects NMDAR-mediated SSCTs. 
The genetically encoded ratiometric calcium indicator GCaMP-6s-R was used to 
detect SSCTs. Cells were bathed in Mg2+-free ACSF containing 1 µM TTX to block evoked 
neurotransmitter release. Dendritic structures were imaged as described in Methods and 
shown in Figure 1B. Individual dendritic spines were identified in the mCherry image and 
regions of interest (ROIs) selected manually. Figure 4.1C shows traces from 8 ROIs that 
exhibited SSCTs and identified in Figure 4.1B by matching colored arrows. In control 
recordings the SSCT amplitude increased slightly in the second 2 min epoch relative to 
the first although this trend was not statistically significant (Figure 4.1D). The SSCT 
frequency was also similar in the first relative to the second epoch (Figure 4.1E control). 
Superfusion with ACSF containing the NMDAR antagonist APV (50 µM) or ACSF 
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containing 1 mM Mg2+ completely blocked the SSCTs (Figure 4.1C and E), indicating that 
the detected events are mediated by NMDARs. 
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Figure 4.1 Ratiometric GCaMP-6s-R detects NMDAR-mediated SSCTs. (A) 
Representative traces show calibration of ratiometric GCaMP-6s-R. Hippocampal neurons 
were bathed in modified ACSF as indicated. Ionomycin cocktail (final concentrations: 5 
µM ionomycin, 1 µM FCCP and 10 µM cyclopiazonic acid) was applied directly to a static 
bath at the times indicated by the arrows. Rmin and Rmax were determined from the lowest 
and highest [Ca2+]i, respectively. Inset shows ROIs color coded to match traces overlaid 
on red channel image. (B) Representative red channel image of a neuron expressing 
GCaMP-6s-R. Inset is enlarged image of the boxed region. Arrows placed over active 
spines for analysis are color-coded to corresponding traces in C. Scale bars represent 10 
µm. (C) Representative traces indicating amplitude and frequency changes of SSCTs 
before and after perfusion with 50 µM APV (arrow) for the spines labeled in Figure 1B. (D) 
Bar graph and trend lines indicating changes in amplitude of SSCTs for the same field 
perfused with control ACSF (paired two-tailed t-test; t(5) = 1.1, p = 0.33, n = 6; data from 
three independent culture preparations). (E) Bar graphs and trend lines indicating changes 
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in the frequency of SSCTs before and after perfusion with control ACSF (paired two-tailed 
t-test; t(5) = 0.91, p = 0.41, n = 6; data from three independent culture preparations), and 
ACSF containing 50 µM APV (paired two-tailed t-test; t(6) = 3.5, p = 0.013, n = 7; data from 
three independent culture preparations) or supplemented with 1 mM Mg2+ (paired two-
tailed t-test; t(5) = 3.0, p = 0.03, n = 6; data from three independent culture preparations). 
Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01, compared with the same fields 
before treatments (paired two-tailed Student’s t-test, n = number of individual dishes in 
each group). 
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SSCTs are regulated by GluN2B-containing NMDARs 
To determine the subtype of NMDARs controlling SSCTs, Ro 25-6981, a potent 
and selective antagonist of GluN2B-containing NMDARs was added to the extracellular 
solution (Mg2+-free ACSF containing 1 μM TTX) (Fischer et al., 1997). SSCTs for the same 
dendritic structure were imaged and analyzed for changes in frequency and amplitude 
before and after treatment with 0.1 µM Ro 25-6981. Representative traces for ROIs of all 
active spines in an individual field are shown in Figure 4.2A. Event frequency and 
amplitude of SSCTs calculated for 7 recordings are shown before and after application of 
0.1 µM Ro 25-6981 (Figure 4.2B-C). Ro 25-6981 (0.1 µM) significantly decreased the 
event frequency by 49 ± 10% but did not significantly affect the amplitude (net change in 
[Ca2+]i) of the SSCTs. A change in event frequency without affecting amplitude is 
consistent with a presynaptic site of action. To further test this possibility, the 
concentration-response relationship for Ro 25-6981 was determined using the same 
approach. Various concentrations of Ro 25-6981 (0, 0.1, 1, 10 µM) were applied to 
neurons exhibiting SSCTs and changes in frequency and amplitude determined. Ro 25-
6981 produced a concentration dependent inhibition of SSCT frequency with an IC50 of 
0.21 µM, in good agreement with the reported IC50 of 0.4 µM for Ro 25-6981 inhibition of 
glutamate neurotoxicity (Fischer et al., 1997). Ro 25-6981 at the highest concentration (10 
μM) blocked 88 % of the spontaneous SSCT events, suggesting that presynaptic GluN2B 
NMDARs regulate these events. Ro 25-6981 did not significantly affect the amplitude of 
SSCTs at any concentration tested (Figure 4.2D). These results are consistent with 
presynaptic inhibition of glutamate release in the absence of postsynaptic action. 
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Figure 4.2 Ro 25-6981 reduces the frequency but not amplitude of SSCTs. (A) 
Representative traces showing SSCTs before and after perfusion of 0.1 µM Ro 25-6981. 
(B-C) Bar graphs and trend lines indicating reduced frequency (B) (paired two-tailed t-test; 
t(6) = 3.1, p = 0.021, n = 7; data from six independent culture preparations) but not 
amplitude (C) (paired two-tailed t-test; t(6) = 0.39, p = 0.71, n = 7; data from six independent 
culture preparations) of SSCTs by treatment with 0.1 µM Ro 25-6981. (D) Bar graphs 
indicating dose-dependent change in the frequency (One-way ANOVA; F(3,24) = 10.42, p = 
0.0001, n = 7 for each group; data from six independent culture preparations) but not 
amplitude (One-way ANOVA; F(3,24) = 0.52, p = 0.68, n = 7 for each group; data from six 
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independent culture preparations) of SSCTs after treatment with the indicated 
concentrations of Ro 25-6981. Data are expressed as mean ± SEM. Unpaired two-tailed 
Student’s t-test or One-way ANOVA followed by Tukey's post hoc test, *p < 0.05, 
**p < 0.01, ***p < .001 compared with control (0 µM Ro 25-6981 treatment) (n = number of 
individual dishes in each group). 
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Inhibition of presynaptic GluN2B-containing NMDARs increases the number of 
synaptic connections when evoked release is blocked 
Previous studies from our lab have demonstrated that blocking GluN2B-containing 
NMDARs with the selective antagonist ifenprodil induces recovery of synaptic connections 
lost during exposure to a neurotoxic protein (Shin et al., 2012; Raybuck et al., 2017). 
Furthermore, Crawford et al. (2017) have shown that blocking spontaneous glutamate 
release when evoked release is also blocked will increase synaptic strength. Because Ro 
25-6981 inhibited spontaneous glutamate release (Figure 4.2), we examined whether this 
drug might stimulate synaptogenesis under conditions in which evoked neurotransmitter 
release is blocked. To detect changes in the number of synapses, cells were transfected 
with expression plasmids for an eGFP-tagged recombinant antibody-like protein 
(PSD95.FingR-eGFP) to selectively label the post-synaptic density of excitatory synapses 
and a red fluorescent protein (tdTomato) to fill the cell structure. The number of labeled 
synapses was determined using an algorithm that counted fluorescent puncta that met 
size and intensity thresholds and were in contact with a mask derived from the tdTomato 
image (Waataja et al., 2008). PSD95.FingR-eGFP was previously shown to label 
functional synapses (Zhang and Thayer, 2018) enabling this live-cell imaging-based assay 
to track the number of synapses on the same neuron over time. The number of synaptic 
connections in untreated cultures (control) and cultures treated with 1 µM TTX did not 
change significantly over 24 h (Figure 4.3A-B). Treatment with the combination of 1 µM 
TTX and 10 µM Ro 25-6981 for 24 h increased the number of synapses by 15 ± 6 % which 
was significantly different compared to control which decreased by 6 ± 5 % (Figure 4.3A-
B). In a separate cohort of cells, treatment with 10 µM Ro 25-6981 alone did not increase 
the number of synapses (Figure 4.3C). These data indicate that blocking presynaptic 
GluN2B-containing NMDARs when evoked neurotransmitter release is also blocked 
stimulates new synapse formation. 
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Figure 4.3 Treatment with Ro 25-6981 in the presence of TTX increased the number 
of excitatory synapses. (A) Representative processed confocal images showing 
neurons before (0 h) and after no treatment (control) or treatment with either 1 µM TTX or 
both TTX and 10 µM Ro 25-6981 for 24 h. The images are processed as described in 
Materials and Methods. Identified PSD95 puncta (green) are dilated and overlaid on the 
tdTomato maximum projection images for display purposes. Insets are enlarged images 
of the boxed regions. Scale bars represent 10 µm. (B) Treatment with 10 µM Ro 25-6981 
in the presence of 1 µM TTX increased the number of intrabody-labeled PSD95 puncta 
(One-way ANOVA; F(2,27) = 5.5, p = 0.01, n = 10 for each group; data from three 
independent culture preparations). (C) Treatment with 10 µM Ro 25-6981 alone does not 
influence the number of PSD95 puncta (unpaired two-tailed t-test; t(20) = 0.18, p = 0.86, n 
= 11; data from three independent culture preparations). Data are expressed as mean ± 
SEM. Unpaired two-tailed Student’s t-test or One-way ANOVA followed by Tukey's post 
hoc test, *p < 0.05 compared with control; #p < 0.05 compared with TTX treated group (n 
= number of individual dishes in each group). 
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IV. Discussion 
Spontaneous neurotransmission regulates synaptic strength and during 
development controls synapse formation (Crawford et al., 2017; Ramirez et al., 2017; 
Andreae and Burrone, 2018). Ro 25-6981, an antagonist for GluN2B-containing NMDARs, 
reduces spontaneous and evoked glutamate release in visual cortex, although via different 
signaling mechanisms (Abrahamsson et al., 2017). In this study, we examined the role of 
GluN2B-containing NMDARs in regulating SSCTs and synaptogenesis. We found that 
presynaptic GluN2B-containing NMDARs regulate the spontaneous release of glutamate, 
and that blocking these receptors initiates the formation of new synapses. 
This imaging-based study used state of the art genetically encoded fluorescent 
reporter proteins to quantify SSCTs and the number of synapses. The structure of 
GCaMP-6s-R links the Ca2+ indicator GCaMP-6s to Ca2+-insensitive mCherry (Cho et al., 
2017). Thus, the ratio of green to red fluorescence intensity is related to [Ca2+]i in a manner 
that is independent of the expression level of the indicator and thickness of the sample. 
This indicator enabled accurate quantification of the amplitude of SSCTs providing a 
method to show that Ro 25-6891 affected the frequency of spontaneous events but not 
the amplitude of the [Ca2+]i transients. This presynaptic role for GluN2B-containing 
NMDARs is consistent with studies in visual cortex (Abrahamsson et al., 2017) and the 
lack of postsynaptic effects of Ro 25-6891 in hippocampal cultures may result from the 
developmental switch from GluN2B- to GluN2A-containing NMDARs in the postsynaptic 
density (Stocca et al., 2008). We used a recombinant antibody-like protein, PSD95.FingR-
eGFP, to label post-synaptic density protein PSD95 as a method to track changes in the 
number of functional excitatory synapses in live cells (Gross et al., 2013; Zhang and 
Thayer, 2018). This method allowed visualization of synaptic sites before and after 
treatments that blocked evoked and spontaneous glutamate release. Only when evoked 
and spontaneous glutamate were both inhibited did a significant increase in synaptic 
number occur. 
The observation that new synapses form when glutamatergic synaptic 
transmission is inhibited is consistent with a form of homeostatic scaling (Keck et al., 
2017). Modulation of spontaneous glutamate release has been implicated in this form of 
plasticity (Kavalali, 2015) and is consistent with studies that found selective block of 
spontaneous neurotransmission induced potentiation of glutamatergic synaptic strength 
(Nosyreva et al., 2013; Crawford et al., 2017; Ramirez et al., 2017). However, our results 
differ from these studies in that only when evoked glutamate release was blocked with 
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TTX did Ro 25-6891 stimulate new synapse formation. This difference may be due to 
different mechanisms strengthening existing synapses versus stimulating the formation of 
new connections. Blocking evoked neurotransmission with TTX will induce upscaling 
under certain conditions (Hargus and Thayer, 2013), although the 24 h treatment used in 
this study did not induce synapse formation. Spontaneous neurotransmitter release plays 
a different role in maintaining synaptic homeostasis in established networks from its role 
in building new networks. During development spontaneous neurotransmitter release 
enhances the elaboration of dendritic arbors and is required for the development of normal 
axon terminals (Andreae et al., 2012; Andreae and Burrone, 2015). These roles are 
contrary to the results described here and in other studies of mature neurons (Li et al., 
2010; Autry et al., 2011; Kavalali and Monteggia, 2012; Nosyreva et al., 2014). Clearly, 
there are multiple mechanisms to maintain synaptic homeostasis with distinct processes 
participating under various conditions. 
The possibility that impaired spontaneous synaptic transmission is necessary for 
stimulating new synapse formation by antagonists of GluN2B-containing NMDARs may 
be important in certain disease states. Decreased synapse density correlates with 
symptom severity in depressed human subjects and with cognitive decline in several 
neurodegenerative diseases (Ellis et al., 2007; Serrano-Pozo et al., 2011; Holmes et al., 
2019). In animal models, antagonists for GluN2B-containing NMDARs increase spine 
density and reverse cognitive impairment and depression-like behaviors (Miller et al., 
2014; Raybuck et al., 2017). Blocking spontaneous neurotransmission may underlie the 
synaptic potentiation and fast antidepressant effects produced by ketamine (Autry et al., 
2011; Nosyreva et al., 2013). In a mouse model of HIV-associated neurocognitive 
disorder, the synapse loss and cognitive impairment induced by the HIV protein Tat was 
reversed by ifenprodil, an antagonist for GluN2B-containing NMDARs (Shin et al., 2012; 
Raybuck et al., 2017). Interestingly, in the absence of neuropsychiatric impairment, 
antagonists for GluN2B-containing NMDARs do not stimulate synapse formation or 
improve cognition (Raybuck et al. 2017). Thus, the synaptogenic actions of antagonists 
for GluN2B-containing NMDARs are enhanced when evoked synaptic transmission is 
impaired. Perhaps an enhanced role of spontaneous neurotransmitter release under this 
condition accounts for this state-dependent pharmacology. 
In summary, we have shown that inhibition of presynaptic GluN2B-containing 
NMDARs, under conditions where evoked glutamate release is blocked, stimulates new 
synapse formation in an established synaptic network. We speculate that targeted 
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inhibition of these presynaptic receptors when neuropathology impairs normal evoked 
neurotransmission, might restore synaptic density. 
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Chapter Five: Concluding Remarks 
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I. Summary of current studies 
The studies described in this dissertation expand our understanding of gp120-
induced changes in excitatory and inhibitory synapses using primary cultured hippocampal 
cells and demonstrated that modulation of the eCB system and NMDAR subtypes have 
therapeutic potentials for protecting neuronal function in HAND. HIV gp120-caused 
excitatory synapse loss has previously been described (Kim et al., 2011). In the second 
chapter, I further demonstrated that gp120-induced activation of microglia and release of 
IL-1β potentiates NMDAR-mediated Ca2+ influx leading to loss of excitatory synapses. 
Inhibition of MGL of the eCB system was previously shown to enhance 2-AG levels 
decreasing neuroinflammation (Nomura et al., 2011; Kerr et al., 2013). I showed that 
pharmacological inhibition of MGL using the selective inhibitor JZL184 blocked gp120-
induced release of IL-1β and loss of excitatory synapses. Blocking MGL suppress gp120-
mediated neuroinflammation through both activation of CB2Rs and decreased production 
of PGE2 (Zhang and Thayer, 2018). 
Excitatory synapse loss induced by HIV neurotoxins occurs through pathways 
distinct from those leading to neuronal death (Kim et al., 2008b); we previously speculated 
that this type of functional loss can be part of an overactivated coping mechanism to 
maintain network homeostasis (Kim et al., 2008b; Shin et al., 2012; Shin and Thayer, 
2013). Balance between excitatory and inhibitory synapses is also part of neuronal 
homeostasis (Liu, 2004; Turrigiano, 2012) and is important for maintaining normal 
cognitive function (Nelson and Valakh, 2015; Zorrilla de San Martin et al., 2018). Few 
studies have focused on HIV neurotoxin-induced changes in inhibitory synapses (Fitting 
et al., 2013; Hargus and Thayer, 2013; Green and Thayer, 2019). In chapter three, I 
discovered that gp120 increased the number of inhibitory synapses through microglial 
activation and subsequent release of IL-1β. GluN2A NMDARs mediate the change and 
overcome the p38 MAPK regulated suppression of inhibitory synapse density. 
The work in chapter three and previous studies indicate that GluN2A-containing 
NMDARs are involved in HIV neurotoxin-induced loss of excitatory and increase in 
inhibitory synapse number (Shin et al., 2012; Hargus and Thayer, 2013; Zhang et al., 
2019). This led me to investigate the role of subtypes of NMDARs in synaptogenesis. In 
chapter four, I discovered that presynaptic GluN2B-containing NMDARs regulates 
spontaneous release of glutamate and that inhibition of these presynaptic NMDARs 
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induces synaptogenesis. This work provides new insights on targeting NMDAR subtypes 
for development of neuroprotective agents. 
II. Advantages and limitations of current study 
In the second and third chapter, I utilized a live cell imaging-based assay to track 
the number of excitatory and inhibitory synapses in cultured hippocampal neurons during 
treatments. This technique was established and demonstrated to label functional 
synapses by previous work from our lab (Kim et al., 2008b; Kim et al., 2011; Shin et al., 
2012; Hargus and Thayer, 2013). In the current studies, I updated the assay by 
incorporating a fluorescent recombinant antibody-like protein (intrabody) to bind to and 
label the endogenous excitatory and inhibitory post-synaptic scaffolding proteins PSD95 
and gephyrin, instead of using fusion proteins that introduce exogenous production of 
these proteins (Gross et al., 2013). This technique has several advantages. First, it allows 
the experiments to be performed on living neurons. To investigate changes in the number 
of excitatory and inhibitory post-synaptic densities, cultures or tissues are usually fixed to 
allow immunolabeling of relevant proteins (Ellis et al., 2007); comparisons need to be 
made between different neurons receiving different treatments. Our assay allows direct 
comparison of the same cell before and after treatments. Additionally, an automated 
algorithm to count the number of labeled excitatory and inhibitory synapses was applied 
in our assay. This allows experimenters to be blinded during the data analysis. Third, the 
use of intrabody avoided potential increase of synapse number driven by expression of 
exogenous fusion proteins and was demonstrated to label functional excitatory and 
inhibitory synapses by immunocytochemistry and electrophysiological assays (Gross et 
al., 2013; Zhang and Thayer, 2018; Zhang et al., 2019). Thus, this assay is a powerful tool 
to understand the signaling pathways that modulate synaptic changes. 
In the fourth chapter, I developed a spine calcium imaging assay that employs a 
ratiometric genetically-encoded Ca2+ indicator, GCaMP-6s-R. Compared to traditionally 
used non-ratiometric genetically-encoded Ca2+ indicators such as GCaMP-6s, this 
indicator allows detecting both amplitude and frequency changes in spine calcium 
transients before and after treatments. Imaging of NMDAR-mediated spontaneous spine 
calcium transients gives a direct visualization of release events occurring at individual 
spines providing both spatial and temporal information not acquired with conventional 
electrophysiology methods. 
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These studies, however, have limitations. Primary hippocampal cultures provide a 
simple and easily accessible system to probe and explore detailed signaling pathways for 
gp120-induced synaptic changes. The simple system does not incorporate properties of 
whole animal models or signaling unique to the human species. Thus, the findings need 
to be confirmed in vivo. In fact, previous studies from our lab have confirmed successful 
translation of in vitro work to in vivo (Raybuck et al., 2017). Furthermore, the current study 
focuses on gp120 and uses 600 pM of the protein for treatments. This concentration, 
although consistent with what is used in other studies (Meucci and Miller, 1996; Viviani et 
al., 2001; Viviani et al., 2006; Medders et al., 2010), may not mimic the real concentration 
of gp120 in brains of HAND patients which is currently not known. Thus, although the 
current study of gp120-induced release of IL-1β model largely mimics neuroinflammation 
in HIV patients (Xing et al., 2009; Walsh et al., 2014), more studies are needed to confirm 
the clinical relevance of the model. 
III. Future directions and therapeutic potential of targeting the eCB system and 
NMDARs 
More work is needed to fully discover the complete mechanisms for 
synaptodendritic damage-induced by HIV viral proteins and pro-inflammatory factors. 
Current studies uncovered changes in number of excitatory and inhibitory synapses as 
part of a potential homeostatic plasticity mechanism to counterbalance enhanced 
excitation. Whether other forms of coping mechanisms such as synaptic scaling to 
regulate the strength of individual synapses and regulation of intrinsic excitability are 
involved, and how these processes are coordinately controlled leading to loss of cognitive 
function need to be further investigated. Whether increases in inhibitory synapses 
correlate with cognitive dysfunction remains unclear and its clinical relevance needs to be 
established in human and animal models. Additionally, if loss of excitatory synapses is 
part of a survival mechanism for neurons, whether blocking this process and inducing 
recovery renders neurons more vulnerable to death need to be cautiously studied for 
developing therapeutic strategies. Whether there is a threshold for homeostatic 
adjustment of synapses, which is sufficient to counteract excessive excitation and support 
neuronal survival but also avoids loss of network function-associated with synapse loss, 
is important for future research. 
Inhibition of MGL enhances CB2R activation and decreases PGE2 production 
suggesting eCB system as a target to reduce neuroinflammation in HIV patients. Inhibition 
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of MGL was specifically associated with protection of excitatory synapses in the current 
studies, and this same drug treatment induced excitatory synapses recovery improving 
cognitive function in an Alzheimer’s disease animal model (Chen et al., 2012). In fact, 
increased expression of CB2Rs in HIV-infected individuals (Benito et al., 2005; Cosenza-
Nashat et al., 2011) and elevated PGE2 levels in HIV-infected animal models (Blanchard 
et al., 2015) are reported; these reports further support the therapeutic potential of MGL 
inhibition. A highly potent, orally available MGL inhibitor, ABX-1431, is currently being 
investigated in a phase II trial for treatment of Tourette Syndrome suggesting this class of 
drugs is well-tolerated (ClinicalTrials.gov Identifier: NCT03625453). Furthermore, this type 
of drug provides “on-demand” neuroprotection and enhances the function of endogenous 
2-AG, and thus, likely produces fewer psychoactive side effects compared to conventional 
cannabinoid receptor agonists. Despite that, potential side effects still needed to be 
cautiously studied. 
Inhibition of GluN2A NMDARs blocks the loss of excitatory and the increase of 
inhibitory synapses; blocking GluN2B NMDARs induces regeneration of excitatory 
synapses. These studies suggest subtype specific differences in NMDARs that influences 
their potential roles in HAND. Current studies provide an initial insight to the function of 
presynaptic GluN2B NMDARs in synaptogenesis. Whether this is the underlying 
mechanism for GluN2B inhibitor-mediated synapse recovery under HIV neurotoxin-
treated conditions needs to be investigated. The accurate pre-and post-synaptic locations 
of GluN2B and GluN2A NMDARs in hippocampus and their therapeutic roles need to be 
studied and confirmed in whole animal models and humans eventually. 
In conclusion, studies in this dissertation expanded our mechanistic understanding 
of synaptic changes-induced by HIV gp120 and provides novel views for modulation of 
synaptic changes in HAND highlighting the eCB system and NMDAR subtypes as 
promising future directions for the development of neuroprotective agents. 
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